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INTRODUCTION 
 
Abnormal uterine bleeding (AUB) is defined as any uterine bleeding that is 
more than the normal volume, of longer duration and varying in regularity or 
frequency. Nearly 30% of all gynaecological outpatient attendants are for AUB 
(1). 
Abnormal uterine bleeding (AUB) is a collective terminology that includes 
both organic and non-organic causes. Dysfunctional uterine bleeding (DUB) is a 
subgroup of AUB that includes abnormal bleeding due to non-organic causes. It 
is present in 50% of the women with AUB. An endometrial biopsy is usually 
done for abnormal uterine bleeding to rule out organic pathology. Age and 
menstrual history are particularly important, because the etiologies of abnormal 
uterine bleeding differ according to the age and menstrual status (2). In women 
of reproductive age group, pregnancy complications, including abortion are 
more common, whereas in postmenopausal women atrophy and organic 
pathologies are common (3). 
A diagnosis of Dysfunctional uterine bleeding can only be made after the 
histopathological examination has ruled out organic causes (4). Three patterns 
are commonly seen in DUB. The first is called as “estrogen breakthrough 
bleeding”, which occurs in the presence of continuous estrogen production by a 
“persistent follicle”. The proliferated endometrium increase in size so that it 
outgrows its own blood supply and breakthrough bleeding ensues. The second 
one is called “estrogen withdrawl bleeding” which is due to “failed follicle”, i.e. 
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the follicle produces subnormal estrogen. Both these causes are attributed to 
anovulation. The third finding is “ovulatory endometrium” due to follicular or 
luteal phase defects. 
The cyclical release of estrogen and progesterone from the ovaries control 
the normal cyclical physiological changes that occur in the endometrium of 
women during the reproductive period (5). The concentration of receptors for 
these hormones also vary cyclically during the menstrual cycle. Estrogen and 
progesterone receptors are also expressed in hyperplasias and endometrial 
cancers, especially type I. These receptor levels can give important prognostic 
information. They also give information about the amenability to hormonal 
therapy. 
Hormonal imbalance is the main factor involved in the pathogenesis of 
Dysfunctional Uterine Bleeding. This alteration is better studied by a 
combination of histopathological and immunohistochemical evaluation of the 
endometrium (6). 
  
 
 
 
AIMS AND 
OBJECTIVES 
 
 
 
3 
 
AIMS AND OBJECTIVES 
 
1. To determine the histopathological patterns of endometrial curettings in 
women with abnormal uterine bleeding. 
 
2. To categorise the causes of abnormal uterine bleeding according to age 
group and pattern of bleeding. 
 
 
3. To find out Estrogen and Progesterone Receptor status of non-malignant 
and malignant endometrium in the perimenopausal age group. 
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REVIEW OF LITERATURE 
 
 
Normal menstruation is characterised by bleeding from secretory 
endometrium following an ovulatory cycle. It lasts for a duration less than 5 days 
with an average interval of 28 days and blood loss around 35 ml (20–80 ml) (7). 
Any uterine bleeding of large volume, longer duration, and irregular in 
frequency is termed as abnormal uterine bleeding. 
Abnormal uterine bleeding that is not associated with any genital tract 
abnormalities, general or endocrinological diseases is termed as “dysfunctional 
uterine bleeding”. 
The term Heavy Menstrual Bleeding (HMB) is used when bleeding 
interferes with the woman's quality of life in physical, emotional, social and 
maternal aspects. 
Women of all age groups present to the gynaecologist with abnormal 
uterine bleeding. AUB occurs in 9-14% of women of reproductive, 
perimenopausal and postmenopausal age groups. It significantly impairs the 
quality of life and increases financial burden. 
 
PHYSIOLOGY OF NORMAL MENSTRUATION 
Any bleeding not fulfilling the requirements of normal menstruation is 
termed as “Abnormal uterine bleeding” (8). 
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At any menstrual cycle only one oocyte is released. This is followed by 
secretory phase. After a constant period of 14 days after ovulation, there is 
shedding of the secretory endometrium. This manifests as monthly menstruation. 
When an oocyte is fertilised and an embryo is implanted, the process of 
endometrial shedding stops.  
Normal monthly menstruation in a woman indicates that the hypothalamo 
pituitary ovarian axis is intact. Interruption of the axis at any point leads to 
disordered menses (9). Hence an understanding of the physiology of menstrual 
cycle is mandatory. 
MENSTRUAL CYCLE  
Cyclical  menstruation continues  throughout the reproductive era of life 
with an average rhythm of 28 -67 days, inclusive of 4–6 days of bleeding (except 
pregnancy and lactation). 
It can be classified into two cycles 
1. Ovarian cycle  
2. Endometrial cycle 
OVARIAN CYCLE 
During this cycle, a single follicle develops and matures. It then ovulates 
and the remaining cells form the corpus luteum. 
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It can be divided into three phases 
1. Follicular phase 
2. Ovulation phase 
3. Luteal phase 
FOLLICULAR PHASE 
This is the first part of the ovarian cycle. The follicle stimulating hormone 
released from the pituitary stimulates the follicle which matures as a result. 
Under the influence of several hormonal autocrine and paracrine interloops only 
one follicle develops, while all others stop developing. This dominant follicle 
will continue to mature through the sequential stages of primordial, preantral, 
antral and preovulatory graffian follicle. The fully mature follicle is termed as 
tertiary (Graffian) follicle. This follicle contains the ovum. The average length 
of this phase is 14 days but it is not constant. 
OVULATION PHASE 
Ovulation is the process of release of a mature ovum from the ovarian 
follicle. A Sustained peak level of estrogen for 24–48 hours in the late follicular 
phase results in a LH surge from the anterior pituitary (positive feedback effect). 
This process starts around the 12th day of the average cycle and may last 48 
hours. The egg matures under the influence of LH and the wall of the follicle is 
weakened. This results in the release of secondary oocyte from the fully 
developed follicle. Ootid is formed from the secondary oocyte which then 
becomes a mature ovum.   
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LUTEAL PHASE 
This phase starts after the ovum is expelled from the follicle. The 
remaining granulosa and theca interna cells change into lutein cells which 
increase in size and accumulate lipid inclusions. This gives them a yellowish 
appearance. The mass thus formed is called the corpus luteum. The average 
length is 14 days (constant phase) 
Luteo follicular transition 
This period extends from the demise of corpus luteum (fall of serum estradiol, 
inhibin and progesterone level) to the selection of a dominant follicle for the next 
cycle. 
Several hormones are involved in different phases of the menstrual cycle. 
Their levels can be measured in plasma. 
1. Follicle stimulating hormone 
2. Lutinizing hormone 
3. Estrogen 
4. Progesterone 
ENDOMETRIAL CYCLE 
The endometrium is the lining epithelium of the uterine cavity above the 
level of the internal os. It is composed of surface epithelium, glands, stroma and 
blood vessels. The endometrium is an organ where complex interplay between 
immune, endocrine and vascular systems take place (10). 
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Two distinct divisions are established  
1. Basal zone (stratum basalis)  
2. Superficial functional zone 
BASAL ZONE 
It is about one-third of the total depth of the endometrium, supplied by 
the basal arteries uninfluenced by hormone. No cyclic changes are observed in 
this zone. The regeneration of all the components occur from this zone. It 
measures about 1 mm. 
FUNCTIONAL ZONE 
This zone is under the influence of the fluctuating cyclic ovarian hormones, 
estrogen and progesterone. The changes in different components during an 
ovulatory cycle has been traditionally divided into four stages. 
1. Regenerative phase.  
2. Proliferative phase. 
3. Secretory phase. 
4. Menstruation. 
PROLIFERATIVE PHASE  
Under the influence of estrogens, secreted in increasing quantities by the 
ovary during the first part of the cycle, the stromal cells and the epithelial cells 
proliferate. This phase lasts from 5th day to 14th day of a 28 day cycle,but 
subjected to variation under physiological conditions. The average endometrial 
thickness is 2-3mm. 
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Early(5-7days) 
During this phase, the regenerating epithelium is thin. The glands are 
short and narrow with epithelial mitoses. Mitosis is also seen in the stromal cells 
(stromal cells are stellate or spindle shaped) (2). 
Mid (8–10 days) 
The glands are long and curving. The lining epithelium is columnar with  
variable stromal edema and frequent mitoses. 
Late (11–14 days) 
The glands are tortuous.Nuclear pseudostratification  seen. The stroma is  
moderately dense and actively growing. 
SECRETORY PHASE 
The changes of the components are due to the combined effects of 
estrogen and progesterone liberated from the corpus luteum after ovulation. Thus 
progesterone can only act on the endometrium previously primed by the 
estrogen. The length of the secretory phase is constant at 14 days. This is due to 
precise and rhythmically involuting corpus luteum after ovulation. The 
endometrial thickness is maximum at this phase (6–8 mm). 
An interval phase lasts from 14th to 15th day. No noticable changes are 
seen for 36–48 hours after ovulation (2). 
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Early secretory phase, (16–20 ) 
Glandular changes are prominent in this phase.  By 16th  day subnuclear 
vacuoles appear. Regular vacuolation appears around the 17th day. Around 18th 
day vacuoles decrease in size. The lumen is filled with early secretions and the 
nucleus reaches base of the cell. At 19th day, few vacuoles persist and 
intraluminal secretions are seen . Pseudostratification and mitoses are absent. On 
20th day, intraluminal secretions are maximum. 
Mid- to late secretory phase ( 21–27 days) 
Stromal changes are prominent in this phase. Varying degrees of secretory 
exhaustion is seen. On 21st day there is marked stromal edema. On 22nd day, 
stromal edema is at its peak - cells have “naked nuclei”. On 23rd day, 
periarteriolar predecidual change is found and spiral arteries are prominent. On 
24th day, predecidual change is prominent and stromal mitoses recur. On 25th day, 
predecidual differentiation starts beneath the surface epithelium and granular 
lymphocytes increase in number. On 26th day, predecidua starts to become 
confluent. On 27th day, granular lymphocytes are maximum. The sheets of 
predecidua become confluent and focal necrosis appear. Between 24–27 days, 
secretory exhaustion of glands is seen. The glands are tortuous with intraluminal 
tufts giving them a saw-toothed appearance. The luminal borders are ragged and 
filled with secretions. There is variable cytoplasmic vacuolization. 
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MENSTRUAL ENDOMETRIUM 
Regression of the corpus luteum with a fall in the level of estrogen and 
progesterone is an invariable preceding feature of menstrual phase. There is a 
breakdown of endometrial glands and stroma. This is seen throughout the 
functional layer by the end of the 28th day. There is also fibrin thrombi in small 
vessels. The stroma is condensed and collapsed with necrotic debris. 
Neutrophilic infiltration is also seen (11). This inflammatory process is 
completely physiological and strictly regulated (12). The endometrium is 0.5mm 
thick. 
REGENERATION 
Before menstruation ceases, the regeneration of endometrium starts and 
is completed 2–3 days after the end of menstruation. The stromal ground 
substance re-expands. Thickness of the endometrium averages 2 mm (1). 
ENDOMETRIAL ANGIOGENESIS 
Endometrium is the only tissue in the body to undergo rapid growth 
followed by shedding in a cyclical manner. Endometrial angiogenesis depends 
on a delicate balance between factors that promote and inhibit blood vessel 
formation. Estradiol and progesterone control angiogenesis by stimulating or 
inhibiting growth factors. Both these hormones stimulate the production of 
VEGF (vascular endothelial growth factor), which helps in proliferation of 
endometrial vessels. Progesterone stimulates thrombospondin-1, which is 
responsible for the inhibition of blood vessel proliferation during the secretory 
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phase. Withdrawal of hormones estrogen and progesterone releases proteolytic 
enzymes into the extracellular matrix. These enzymes degrade the matrix 
including vessels resulting in menstrual shedding (13). 
DEFINITIONS  
Menorrhagia (hypermenorrhea) 
  Excessive (> 80 mL) and prolonged (>7 days) bleeding occurring at 
regular intervals. 
 Polymenorrhea  
Cyclic bleeding that occurs more frequently than every 21 days and 
persists in that frequency. If there is an associated increase in amount and 
duration of bleeding, it is called epimenorrhagia or polymenorrhagia.  
 Metrorrhagia 
   Cycles are irregular and can manifest as either contact bleeding  or 
intermenstrual bleeding. 
 Menometrorrhagia 
 This term is applied when bleeding occurs erratically and excessively that 
the menstrual phase cannot be determined at all.  
Oligomenorrhea 
Cyclical bleeding that occurs at regular but long (>35 days) intervals. 
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Hypomennorhea 
  When the amount of menstrual bleeding is abnormally small and lasts for 
less than 2 days. 
Intermenstrual bleeding  
This refers to bleeding (usually not  excessive) that occurs between  
otherwise normal menstrual cycles. 
 Precocious menstruation  
Denotes the occurrence of menstruation before the age of 10 years. 
  Postcoital bleeding 
Denotes vaginal bleeding after sexual intercourse. 
EFFECTS OF STEROID HORMONES ON THE ENDOMETRIUM 
Estrogens and progesterone are sex steroids synthesised from cholesterol. 
Mainly progesterone and testosterone are produced first in the ovaries. FSH acts 
on the granulosa cells of the ovary to stimulate aromatase. This enzyme converts 
testosterone and progesterone into estrogens. The principal and the most potent 
estrogen secreted by the ovaries is β-estradiol. 
The size of the uterus increases twofold to threefold after puberty, but 
more important than the increase in uterus size are the alterations that are 
produced in the uterine endometrium under the influence of estrogens. This 
hormone increases the proliferation of the endometrial stroma. The endometrial 
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glands also become well developed. This helps in providing nourishment to the 
implanted ovum. 
Very low levels of estrogen leads to endometrial atrophy, whereas high 
levels lead to hyperplasia.  
Estrogen receptors are located in the nucleus. There are two types of 
estrogen receptors ER α and ER β. These receptors are encoded by two genes, 
namely ESR1 for ER α, and ESR2 for ER β. ER α is present most plentifully in 
the female genital tract, whereas ER β is expressed most abundantly in the 
prostate and ovaries.  
Estrogen receptors are present in both the cytoplasm and the nucleus. 
However, the important functions of estrogen are mediated by the interaction 
with nuclear receptors. Estrogen receptors are bound with a large group of 
proteins called chaperones. When estrogen enters the cell and starts to bind with 
the receptors, these proteins dissociate. After binding of estrogen with their 
receptors, dimerization of the receptors occur. Dimers then bind to estrogen 
responsive elements in the target genes.  
The levels of receptors to these hormones (estrogen and progesterone) are 
independent prognostic factors for endometrial carcinoma. Patients who have 
high levels of these receptors survive longer than patients whose receptor levels 
are low. Liao et al reported that, even for patients with lymph node metastases, 
the prognosis was significantly improved if the tumor was receptor positive. PR 
15 
 
appears to be a stronger predictor of survival than ER and at least for the ER, the 
absolute level of receptors may be important; the higher the level, better the 
prognosis (14). 
METHODS OF ENDOMETRIAL SAMPLING 
DILATATION AND CURETTAGE (D&C) 
For decades, diagnostic curettage has been the most common operation 
performed on women. The procedure is not without its limitations. Hemorrhage, 
infection, and uterine perforation may occur and, because cervical dilatation is 
painful, the risks associated with the necessary general anesthetic are also 
present. 
ENDOMETRIAL BIOPSY 
Removal of a single strip of endometrium may be undertaken as an 
outpatient procedure, without cervical dilatation or general anesthetic. This 
technique is rarely used. 
VABRA ASPIRATOR 
This is a suction curette device composed of a 3–4 mm diameter steel 
cannula that has an opening on one side of its bent tip. The endometrial tissue is 
obtained by suction with an attached syringe. The amount of material this 
procedure captures varies. 
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PIPELLE BIOPSY 
This is probably the most widely used outpatient method in the United 
States and Europe to sample the endometrial cavity. This procedure is quick and 
causes significantly less pain than Novak curette or Vabra aspirator. Although it 
produces less tissue, the diagnostic accuracy of the Pipelle biopsy is similar to 
that of the Vabra aspirator. It is no less reliable than other techniques for 
identifying endometrial carcinoma, although some studies have suggested a poor 
pick-up rate for early, low-volume tumors. 
ENDOMETRIAL RESECTION 
Transcervical resection of the endometrium is one of the different 
methods used for endometrial ablation. It is used as a conservative management 
of abnormal uterine bleeding. It should be done only after excluding hyperplasia 
and carcinoma by other methods of sampling like hysteroscopic biopsy or D&C. 
The endometrium should be supressed hormonally before doing this procedure. 
The tissue obtained is composed mainly of myometrial tissue. However, 
adenomyosis cannot be reliably diagnosed by this procedure. 
ADEQUACY OF SPECIMEN 
A scant specimen is a problem encountered frequently by pathologists 
because of the widespread use of techniques like pipelle biopsy. An adequate 
sample is widely obtained in late proliferative, late secretory, hyperplasias and 
carcinomas. A scant specimen is commonly seen in postmenopausal atrophy. 
Nevertheless, a scant specimen cannot rule out hyperplasia or carcinoma, as 
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cases have been reported in which biopsy has been scanty while subsequent 
hysterectomy has revealed carcinoma.  
It is not necessary to repeat the biopsy when a scant tissue is noted. The 
specimen can be deemed as adequate even when a small amount of endometrial 
tissue is found. It is advisable to use the term unassessable rather than inadequate 
when a scant tissue is seen. McCluggage classified endometrial specimens into 
“inadequate” (no tissue is obtained) and “unassessable” (scant tissue is present). 
This classification holds little significance as the final clinical diagnosis between 
the two categories doesn’t differ significantly (15). The findings of other 
investigations like ultrasound and hysteroscopy should be taken into account 
before going for repeat biopsy in such cases. If the clinical features and other 
investigations point to some pathology, then D&C should be done (5). 
CAUSES OF AUB 
The term Dysfunctional uterine bleeding was previously used to denote 
heavy menstrual bleeding without any organic cause. The term Abnormal 
Uterine Bleeding was introduced by FIGO in 2011 to include all abnormal 
uterine bleeding with or without any organic lesion. The newer classification 
system is known by the acronym PALM–COEIN (16). 
CLASSIFICATION OF AUB 
Contrary to the PALM group, the COEIN group cannot be detected by 
imaging and histopathology. 
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CLASSIFICATION OF AUB (FIGO- 2011) 
Structural causes (PALM) 
Non structural systemic causes 
(COEIN) 
Polyp AUB-P Coagulopathy AUB-C 
Adenomyosis AUB-A 
Ovulatory 
dysfunction 
AUB-O 
Leiomyoma 
- Submucosal 
myoma 
- Other myoma 
AUB-L 
AUB-L SM 
AUB-LO 
Endometrial  AUB-E 
Malignancy and  
hyperplasia 
AUB-M Iatrogenic AUB-I 
  Not yet identified AUB-N 
 
The PALM group includes 4 causes that can be detected by imaging or 
histopathology, whereas the COEIN group includes causes that cannot be 
detected by these modalities (17). 
Polyp (AUB-P) 
Polyps can be detected by ultrasound, hysteroscopy or histopathology. 
They can be subdivided on the basis of number, size, location and histology. 
Adenomyosis (AUB-A) 
 It can be diagnosed by ultrasound or MRI. It is further subdivided on the 
basis of the depth of myometrial invasion. Most often, it is asymptomatic and an 
incidental finding in hysterectomy specimens. 
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Leiomyoma (AUB-L) 
 Leiomyomas usually are not the cause of abnormal uterine bleeding. 
Mostly they are incidental findings. Myomas that are causal in abnormal 
bleeding usually involve the uterine cavity. They are further subdivided into 
primary, secondary and tertiary groups based on their number, size and location. 
Malignancy and pre-malignant lesions 
 It is rare in reproductive age group. In this age group, it occurs usually in 
the setting of polycystic ovarian disease and chronic anovulation. Diagnosis is 
made by histopathological examination of the endometrium (D/C, biopsy). 
Coagulopathy (AUB-C) 
 Coagulopathies are the cause of AUB in 13 to 20 % of women in the 
reproductive age group. The most common cause is Von Willebrand’s disease. 
Ovulatory disorders (AUB-O) 
 Ovulatory disorders are the cause of AUB in 20% of cases. These are the 
result of “Luteal – out – of – phase” events (LOOP) with deficient progesterone. 
Hypothyroidism and hyperprolactinemia are other causes. 
Endometrial causes (AUB-E) 
 Endometrium normally produces prostaglandins from arachidonic acid, 
which is a fatty acid. Of these, PGE2 and PGI2 are vasodilators and antiplatelet 
aggregates. PGF2a and thromboxane A2 cause vasoconstriction and platelet 
aggregates. Progesterone is responsible for the secretion of PGF2a. In 
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anovulatory cycles, the absence of progesterone and thereby of PGF2a causes 
menorrhagia. Rare endometrial causes of AUB include tuberculous endometritis 
and infection, especially chlamydia. 
Iatrogenic (AUB-I) 
 It is caused by steroidal hormones administered as oral contraceptives or 
IUCD. Copper T may cause “break-through bleeding” or menorrhagia. Other 
drugs causing abnormal bleeding include anticoagulants, phenothiazines and 
tricyclic antidepressants. 
Not- classified (AUB-N) 
 This includes rare causes like arteriovenous malformations, varicose 
veins of uterine vessels, myohyperplasia and cases for which no cause can be 
identified by routine investigations 
AUB CAN BE ACUTE OR CHRONIC 
Acute bleeding- may occur sporadically (de novo) or may be 
superimposed on chronic AUB, and requires immediate treatment.   
Chronic AUB - Abnormal menstrual bleeding related to volume, timing,  
regularity and duration of bleeding that lasts for 6 months (minimum 3 months), 
and requires thorough investigations.  
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DYSFUNCTIONAL UTERINE BLEEDING 
The term Dysfunctional Uterine Bleeding is used once the organic causes 
of abnormal bleeding has been excluded. Upto 50% of women with abnormal 
bleeding have DUB (18) . DUB can be classified into 
1. Ovulatory – 10 to 20% 
2. Anovulatory – 80 to 90% 
OVULATORY BLEEDING 
Ovular bleeding can present as either polymenorrhea or menorrhagia. 
Polymenorrhea 
It usually occurs following childbirth and abortion, during adolescence and 
premenopausal period, and in pelvic inflammatory disease. This is due to 
shortening of follicular phase due to hyperstimulation by FSH or premature lysis 
of the corpus luteum. Endometrial study prior to or within few hours of 
menstruation reveals secretory changes 
Menorrhagia 
Two types are seen 
Irregular shedding of the endometrium 
This is due to incomplete and slow degeneration of the corpus luteum 
(Halban’s disease). Endometrial sampling performed after 5th or 6th day of the 
onset of menstruation reveals a mixture of secretory and proliferative 
endometrium. 
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Irregular ripening of the endometrium  
This is due to the poor formation and function of the corpus luteum. 
Endometrial study prior to or soon after spotting reveals patchy areas of secretory 
changes amidst proliferative endometrium. 
ANOVULATORY UTERINE BLEEDING 
Continued exposure to estrogen in the presence of anovulation leads to 
marked endometrial proliferation. After a certain extent, the endometrium cannot 
support the proliferation and shedding occurs called as “anovulatory shedding”. 
This should be differentiated from the normal menstrual shedding. The absence 
of secretory exhaustion and presence of fibrin clots distinguishes anovulatory 
shedding from menstrual endometrium. Also in anovulation the glands lose their 
uniformity in size, shape and distribution leading to a pattern called disordered 
proliferative endometrium. It also leads to cystic dilatation of the glands and 
tubal metaplasia. (19). The underlying cause is unknown. Presumably, the failure 
of ovulation reflects an abnormal gonadotrophin stimulus. 
Metropathia Haemorrhagica 
  It is a specialized form of anovulatory AUB, seen in women between 40 
and 45 years. The basic fault may lie in the ovaries or may be due to a disturbance 
of the rhythmic secretion of the gonadotropins. There is a slow increase in the 
secretion of estrogen but no negative feedback inhibition of FSH. The net effect 
is a gradual rise in the level of estrogen with a concomitant phase of amenorrhea 
for about 6–8 weeks. After a variable period, however, the estrogen level falls 
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resulting in the endometrial shedding with heavy bleeding. Histopathology 
shows thick endometrium with polypoidal projections. There is cystic glandular 
hyperplasia. Some of the glands are small, others are large giving the appearance 
of “Swiss cheese” pattern.  
SPECIFIC CAUSES OF ABNORMAL UTERINE BLEEDING 
ENDOMETRITIS 
 Endometritis commonly occurs in the reproductive age group. It usually 
presents with abnormal uterine bleeding. Predisposing factors include recent 
pregnancy, prior instrumentation, intrauterine devices and cervical stenosis. 
Endometritis may also coexist with polyps, fibroid, hyperplasia or endometrial 
carcinoma. The endometrium shows proliferative activity and glandular 
architectural distortion. There is surface breakdown similar to that seen in 
menstrual breakdown. In low power, the stromal cells show spindle appearance.  
In acute endometritis, the predominant inflammatory cells are 
neutrophils, sometimes seen within the glandular lumina forming 
microabscesses. The characteristic finding of endometritis is the presence of 
plasma cells. Other inflammatory cells like neutrophils and lymphocytes can be 
present in normal endometrium. In chronic endometritis, lymphocytes are 
prominent sometimes forming lymphoid follicles. Endometrial surface and 
glandular epithelium may show metaplastic changes. Immunohistochemistry 
using VS38 or Syndecan can be used to differentiate plasma cells from the 
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endometrial stromal cells, which resembles plasma cells. Plasma cells show 
positivity to both the markers whereas stromal cells positive for only VS38. 
EFFECTS OF EXOGENOUS HORMONAL AGENTS AND DRUGS 
A wide variety of hormonal agents are used in women for various 
indications. The effects of the most common hormonal agents used are discussed 
below. 
ESTROGEN ONLY HORMONE REPLACEMENT THERAPY 
These are rarely used in women because of the risk of endometrial 
hyperplasia and adenocarcinoma. The morphological features include 
proliferative activity similar to disordered proliferation, endometrial hyperplasia 
or endometrioid adenocarcinoma. The risk of carcinoma increases with the dose 
and length of treatment and the adenocarcinoma which develops is usually of an 
early stage and low grade. 
COMBINED ESTROGEN AND PROGESTIN HORMONE THERAPY 
Combined therapy is preferred in women with uterus due to the 
disadvantages of estrogen only therapy (5). Estrogen and progestin combination 
may be given sequentially or simultaneously (continuously). In sequential 
therapy, the endometrium shows weakly proliferative activity during estrogen 
therapy and poorly develop secretory activity during progestin therapy. This 
regimen doesn’t completely abolish the risk of carcinoma and the risk of 
endometrial hyperplasia with sequential regimen is 5.4%. With continuous 
combined regimen, the endometrium shows atrophy or weak secretory activity. 
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This regimen reduces the risk of development of endometrial hyperplasia and 
carcinoma. Hence continuous combined regimen is preferred to sequential HRT 
in perimenopausal women and postmenopausal women. 
PROGESTIN – ONLY COMPOUNDS 
These are commonly prescribed for abnormal uterine bleeding, 
endometriosis, contraception and for endometrial protection in patients taking 
tamoxifen. They usually result in endometrial atrophy with predecidual changes 
or decidualisation of the stroma. 
GONADOTROPHIN RELEASING HORMONE AGONISTS 
These are usually used in the management of uterine fibroids and 
endometriosis. The continuous administration of GnRH agonists results in 
decreased production of FSH and LH thereby causing decreased production of 
estrogen by the ovaries. This results in shrinkage of uterine leiomyomas. The 
endometrium shows atrophy or weak proliferative activity. 
ANDROGENS 
These are used in the treatment of endometriosis, as HRT, menorrhagia 
and endometrial hyperplasia. The endometrium has weak secretory activity 
during the initial phase of treatment but with continued treatment, the 
endometrium shows atrophic changes 
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TAMOXIFEN 
It is used in the prevention and treatment of breast cancer. In the breast, it 
acts as an estrogen antagonist, whereas in the endometrium it acts as a weak 
estrogen agonist. Tamoxifen is associated with a variety of benign and malignant 
lesions in the endometrium. Patients receiving treatment for longer duration and 
at higher doses are particularly at high risk. Benign lesions include polyps and 
hyperplasia. Tamoxifen associated polyps are larger in size. Malignant lesions 
seen with tamoxifen usage are endometrial adenocarcinoma, including both 
endometrioid and serous types and carcinosarcomas. 
ENDOMETRIAL EPITHELIAL METAPLASIA 
Metaplasias are alterations in which the normal endometrial epithelium is 
substituted by a different epithelium. Metaplasias are commonly associated with 
endometrial polyps, exogenous hormone therapy, intrauterine devices, chronic 
endometritis and pyometra. Endometrial metaplasias tend to be associated with 
epithelial hyperplasias or endometrial adenocarcinomas, but by themselves are 
non-neoplastic. WHO classification subdivides endometrial metaplasia into 
mucinous, squamous, ciliary, hobnail, eosinophilic, clear cell, surface syncytial, 
papillary proliferation, and Arias–Stella effect (20). Squamous and mucinous 
metaplasias are particularly common with endometrioid adenocarcinoma.The 
clear cell and papillary syncytial metaplasias must be differentiated from type 2 
endometrial cancers or serous endometrial intraepithelial carcinomas. In serous 
EIC and serous endometrial cancers, immunohistochemistry reveals strong p53 
immunoreactivity while ER is generally negative, whereas the majority of 
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epithelial metaplasias show weak p53 immunoreactivity and strong positivity for 
ER. 
ENDOMETRIAL POLYPS 
These are the cause of uterine bleeding in 2 to 23% of patients undergoing 
endometrial biopsy (21). Polyps can occur at any age, but are most commonly 
seen in the perimenopausal age group. Polyps represent circumscribed foci of 
hyperplasia of the endometrium secondary to hormonal stimulus. Hormone 
replacement therapy and tamoxifen are associated with an increased occurrence 
of polyps. More often the glands and stroma of polyps are non-functional and 
doesn’t respond to hormonal stimulus. Hence, they do not show the cyclical 
changes seen in normal endometrium. Grossly, polyps may be single or multiple, 
sessile or broad based, pedunculated or attached to the endometrium by a slender 
stalk. The histological features of the polyps include the following 
1. Polypoid pieces of tissue lined by epithelium on 3 sides 
2. Stroma altered by fibrosis or excessive collagen 
3. Glands are distended with crowding 
4. Glands out of phase with the adjacent non-polypoidal endometrium ie. in 
a different phase compared with the adjacent endometrium 
5. Blood vessels in the stroma have a thick wall. 
Polyps associated with tamoxifen use are characteristically multiple, large 
and fibrotic and exhibit stromal decidualisation and mucinous metaplasia (22). 
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The differential diagnosis for polyps includes endometrial hyperplasia, 
endometritis, adenosarcoma and adenofibroma. The distinction with endometrial 
hyperplasia is made by examining the stroma. In hyperplasia, the stromal cells 
are active with large vesicular nuclei and occasional mitotic figures, whereas the 
stroma of a polyp is composed of spindle (fibroblast-like) cells and contains 
abundant extracellular connective tissue and large, thick-walled blood vessels. 
Malignant transformation of endometrial polyps is rarely encountered. They can 
present as either in-situ or invasive serous carcinomas (23). 
ENDOMETRIAL HYPERPLASIA 
Definition and classification 
Hyperplasia is characterised by the multiplication of endometrial glands 
of various sizes and shapes which results in higher glandular to stromal ratio. 
There are many classification systems for endometrial hyperplasia. But only the 
Kurman and Norris classification system is commonly used and currently 
approved by the World Health Organization (WHO) (24). It takes into account 
both architectural and cytological features. It is classified into simple and 
complex based on architecture and into typical and atypical based on the 
cytology. 
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Kurman and Norris (1986) classification of endometrial hyperplasia 
Hyperplasia 
 Simple 
 Complex 
Atypical hyperplasia 
 Simple 
 Complex  
WHO classification of endometrial hyperplasia 
Hyperplasia without atypia 
 Simple hyperplasia without atypia 
 Complex hyperplasia without atypia 
Atypical hyperplasia 
 Simple atypical hyperplasia (very rare) 
 Complex atypical hyperplasia 
Clinical features 
Endometrial hyperplasias are most commonly seen in the perimenopausal 
period. It also can be encountered in women in the reproductive age group. 
Hyperplasia develops as a result of unopposed estrogenic stimulation. The 
etiologies for hyperplasia include 
1. Prolonged anovulation 
2. Estrogen only Hormone Replacement Therapy 
3. Obesity 
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4. Polycystic ovarian disease (Stein–Leventhal syndrome) 
5. Granulosa and theca cell tumors of the ovary 
All these causes have in common unimpeded estrogen stimulation.  
Hyperplasias can also occur in postmenopausal woman. Endometrial 
atrophy is the most frequent etiology of AUB in this group of women. In one 
study of postmenopausal bleeding, atrophy was the commonest finding followed 
by hyperplasia and endometrial cancer (25). 
Gross features 
Gross pathological findings are non-specific. Usually the volume of 
curettings is large in hyperplasias. The color is white to tan. It may be seen as 
diffuse thickening or as localised projections into the endometrium, which 
sometimes mimics a polyp. 
HYPERPLASIA WITHOUT ATYPIA 
SIMPLE HYPERPLASIA 
It resembles mid to late proliferative endometrium. The endometrial 
glands vary in size and shape. Some glands show cystic dilatations giving the 
appearance of “swiss-cheese” pattern. This is referred to in older classification 
as cystoglandular hypertrophy. But not all cystic glands are hypertrophied. Some 
cystic glands show atrophy which is called cystic endometrial atrophy (7). The 
stroma is abundant. The epithelial lining is pseudostratified, the nuclei are 
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elongated, chromatin is dispersed and nucleoli are less prominent. The epithelial 
lining shows little budding. 
COMPLEX HYPERPLASIA 
In complex hyperplasia, the glands are densely packed with back to back 
arrangement. The glandular structures are increased in relation to the stroma, 
which is decreased. The glands show more structural complexity with more 
branching in the form of outfoldings and inpouchings. Cytologically the 
glandular epithelial cells are identical to that of simple hyperplasia. 
ATYPICAL HYPERPLASIA 
The presence of atypical nuclei is an important finding due to the risk of 
development of carcinoma. Atypical nuclei are rounded, pleomorphic, show 
stratification with loss of polarity and have condensed chromatin with prominent 
nucleoli giving a vesicular appearance. Atypia may not be seen in all glandular 
epithelial cells. Occasional atypical cells can be ignored. Metaplastic changes 
are often found in association with atypical hyperplasia. The presence of 
histiocytes in the stroma gives a clue to diagnose hyperplasia in asymptomatic 
postmenopausal women. 
ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA (EIN) 
EIN comes under a different type of classification system of hyperplasia. 
It is a premalignant lesion for endometrial carcinoma. It is diagnosed on the basis 
of clinical, histomorphometric, molecular and genetic factors. EIN represents 
monoclonal proliferation of cells with growth advantage conferred by mutations. 
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These cells are able to grow without hormonal support. Although EIN cannot be 
equated with a single diagnosis in WHO classification, it mostly corresponds to 
complex atypical hyperplasia followed by complex hyperplasia. 
Differential diagnosis 
These includes disordered proliferative phase, tubal metaplasia, polyps, 
cystic atrophy and endometrial breakdown. Atypical hyperplasia should be 
differentiated from well differentiated adenocarcinoma and atypical polypoid 
adenomyoma. Distinction between atypical hyperplasia and adenocarcinoma is 
made out by looking for the stromal invasion which is present in the latter. 
Behaviour 
Hyperplasia without atypia usually regress. Atypical hyperplasia is 
associated with a high risk of developing adenocarcinoma. In one study, 23% of 
atypical hyperplasia progressed to carcinoma whereas in the absence of atypia 
the risk of progression to carcinoma decreases to 2% atypia (26). If 
adenocarcinoma develops from atypical hyperplasia, it is usually well 
differentiated and focal with little invasion of the myometrium. It is important to 
note that adenocarcinoma may be co-existant with CAH (25%) (found on 
hysterectomy) or may evolve from hyperplasia (30%). Age of the patient is also 
an important factor influencing the behaviour of hyperplasia. Most of the simple 
hyperplasia in young women regress. 
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Relationship with carcinoma 
1. Most cases of endometrial carcinoma of the endometrioid type are 
preceded by a stage of hyperplasia. 
2. Overall, relatively few patients with hyperplasia will subsequently 
develop cancer. Rather, the majority of the cases are responsive to 
progestin treatment. 
3. The more severe the hyperplasia, the more likely it is to be followed by 
(or to be concurrent with) carcinoma. 
MANAGEMENT OF HYPERPLASIA 
The factors which determine the treatment of endometrial hyperplasia 
include the age of the patient, the histologic type and fitness for surgery 
(especially in postmenopausal women). 
PREMENOPAUSAL WOMEN 
Distinguishing between CAH and endometrial adenocarcinoma is very 
important especially in premenopausal women who wish to retain their fertility. 
Premenopausal women with abnormal bleeding should be considered for 
endometrial biopsy only if they have risk factors like polycystic ovarian disease 
or obesity as there is a low risk of having carcinoma in this age group. 
Hyperplasia without atypia can be treated conservatively with cyclical progestin. 
They should be followed up after 6 months with endometrial sampling to look 
for regression (26).  Women with atypical hyperplasia can be treated with 
progestin suppression if they wish to retain their fertility. However, they should 
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have close follow-up with periodic endometrial samplings. Conservative 
management can also be offered to women with well differentiated carcinoma. 
Hormonal therapy with progestin for 9 months resulted in the regression of 
lesions in 75% of women with carcinoma (27). 
PERIMENOPAUSAL WOMEN (40 – 55 YEARS) 
These women should be considered for an endometrial biopsy even 
though there is also at low risk of developing carcinoma. Women with atypical 
hyperplasia in this age group should be started on hormonal therapy with 
progestins. However, they should be followed up with endometrial biopsies 
every 3 months. Hysterectomy should be performed when hyperplasia persists 
in follow-up biopsy.  
POST MENOPAUSAL WOMEN (OVER 55 YRS OF AGE) 
 Women in this age group have a significantly higher risk of developing 
adenocarcinoma or atypical hyperplasia. Endometrial biopsy should be 
performed followed by fractional curettage if hyperplasia is present. If 
hyperplasia without atypia is detected on curettage, conservative management 
includes observation only or treatment with progestin. Repeated episodes of 
irregular bleeding unresponsive to hormonal treatment requires hysterectomy. If 
atypical hyperplasia is detected, hysterectomy is the management of choice. In 
women unfit for surgery, continuous treatment with progesterone acetate can be 
used to avoid surgery. For postmenopausal women on exogenous estrogens who 
show hyperplasia on biopsy, termination of treatment is usually sufficient to 
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cause regression. Alternatively, a cyclical or continuous administration of 
medroxyprogesterone can be considered to reduce the risk of carcinoma. 
ENDOMETRIAL INTRAEPITHELIAL CARCINOMA (EIC) 
EIC is the precursor of serous endometrial carcinoma. It is an 
intraepithelial malignancy with focal or diffuse involvement of the surface and 
glandular epithelium. The nuclei are hobnail shaped and show marked atypia. 
Sometimes they are associated with metastatis, especially to peritoneal surfaces. 
Hence they are not in situ carcinomas. The presence of disseminated disease is 
an important prognostic factor. So Wheeler et al combine EIC with serous 
carcinom measuring < 1 cm and gave the terminology “minimal uterine serous 
carcinoma” (28) . They can be differentiated from serous carcinoma by the 
absence of stromal invasion. It usually occurs in the setting of endometrial 
atrophy seen in older, postmenopausal women. EIC is often present on the 
surface of a polyp. Immunohistochemistry shows intense reactivity for p53.  
Behaviour 
EIC commonly coexists with invasive carcinoma, usually serous type. 
EIC or serous carcinoma without evidence of metastasis has a very good 
prognosis. The presence of evidence of extrauterine disease implies a bad 
prognosis. Hence, it is important to do a thorough staging at the time of 
hysterectomy when a diagnosis of EIC is made by biopsy. 
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CARCINOMA OF THE ENDOMETRIUM 
Endometrial carcinoma has emerged as the commonest gynaecologic 
malignancy in developed countries. This is because of the increased incidence of 
risk factors like obesity and longer survival of women (29). However, in 
developing countries cervical cancer continues to be the commonest malignancy 
of the genital tract. Endometrial carcinoma usually presents in the early stages 
with abnormal vaginal bleeding. Hence they are amenable to curative therapy by 
hysterectomy. It is mainly a disease of postmenopausal women. 
ENDOMETRIAL ADENOCARCINOMA, ENDOMETRIOID TYPE 
(TYPE I) 
These are the most common type of endometrial cancers accounting for 
about 80% of cases. They usually occur in 55- 65 years of age, slightly younger 
than type II cancers. They usually occur in association with the estrogen related 
risk factors described below (30). The precursor lesion is atypical hyperplasia or 
endometrial intraepithelial neoplasia. These tumors are usually of low grade. 
They are less invasive and have less propensity for lymphatic spread. The 
prognosis is generally good. The genetic alterations include PTEN mutations, 
microsatellite instability and K-ras mutation. 
ENDOMETRIAL ADENOCARCINOMA, NON-ENDOMETRIOID TYPE 
(TYPE II) 
Non-endometrioid tumors occur in older, postmenopausal women, and 
account for 10–20% of endometrial carcinomas. They are not associated with 
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clinical evidence of estrogen stimulation, and usually arise from atrophic 
endometrium. These tumors include serous carcinoma, clear cell carcinoma and 
other histologic subtypes. They are usually poorly differentiated (grade 3) 
tumors. They arise frequently in the setting of endometrial polyps. They have 
rapid courses, a high degree of nuclear pleomorphism and frequent aneuploid 
DNA content. These tumors are aggressive with deeper myometrial invasion and 
increased risk of lymphatic dissemination. The prognosis is generally poor. 
Mutations in the tumor suppressor TP53 are present in at least 90% of serous 
endometrial carcinoma. 
A modified version of the recent World Health Organization (WHO) and 
International Society of Gynecological Pathologists (ISGYP) classification of 
endometrial carcinoma is shown below. 
CLASSIFICATION OF ENDOMETRIAL CARCINOMA 
1. Endometrioid adenocarcinoma 
2. Serous carcinoma 
3. Clear cell carcinoma 
4. Mucinous carcinoma 
5. Villoglandular 
6. Secretory 
7. Ciliated cell 
8. Endometrioid adenocarcinoma with squamous differentiation 
9. Squamous carcinoma 
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10. Mixed types of carcinoma 
11. Undifferentiated carcinoma 
RISK FACTORS FOR ENDOMETRIAL CARCINOMA 
ESTROGENS 
Estrogens are an important stimulus for the development of endometrial 
hyperplasia and adenocarcinoma. The widespread use of estrogens in HRT for 
peri and post menopausal women has resulted in a sudden rise in the incidence 
of endometrial cancers. The risk of developing endometrial cancer is elevated 
three- to sixfold in women taking unopposed estrogens (31), rising to 9.5-fold if 
unopposed estrogen has been used for 10 years or longer (32). The increase risk 
can be alleviated by the addition of progestins for 7 to 10 days a month in women 
taking estrogen for HRT.  
TAMOXIFEN 
Tamoxifen is a selective estrogen receptor modulator used as adjuvant 
therapy for breast cancer. In women of child-bearing age, it antagonises 
estrogens, whereas in post-menopausal women, it has a weak estrogenic effect. 
Tamoxifen administration is associated with an overall slightly increased risk 
(two to three times) of endometrial adenocarcinoma (33). 
POLYCYSTIC OVARY SYNDROME (PCOS) 
PCOS is characterised by atleast two of the following features: 
anovulation or infrequent ovulation, androgen excess, and polycystic ovaries. 
The patients are usually infertile, have elevated estrogen levels, and associated 
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insulin resistance may cause type 2 diabetes. Endometrial carcinoma occurs in 
less than 5% of those women with polycystic ovaries (34). 
OBESITY 
 It is a significant risk factor for the development of endometrial cancer. 
The increase risk may be due to increased peripheral conversion of androgens to 
estrogens (estrone and estradiol) in adipose tissue and decreased levels of serum 
sex hormone binding globulin (SHBG). 
SEX CORD-STROMAL TUMORS 
Granulosa cell tumors and thecoma are associated with a prolonged, 
excessive and unopposed estrogen production. This produces endometrial 
hyperplasia, EIN and endometrial carcinoma. 9–13% of women with granulosa 
cell tumors develop endometrial carcinomas (35). 
NON-NEOPLASTIC OVARAIN LESIONS 
Endometrial carcinoma is found in over one-third of women with diffuse 
hyperthecosis. 
REPRODUCTIVE FACTORS 
Nulliparity is a strong risk factor for endometrial carcinoma. Infertility, 
particularly when it is coupled with anovulation and progesterone deficiency is 
also a risk factor for development of endometrial adenocarcinoma. Early 
menarche, late menopause and low parity are factors associated with increased 
overall lifetime estrogen exposure. 
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SYNDROMES 
  Endometrial carcinoma can rarely be a manifestation of hereditary cancer 
syndromes like Hereditary Non-polyposis Colonic Cancer syndrome (HNPCC 
or Lynch syndrome) and Cowden syndrome. 
The use of oral contraceptives reduces the risk of endometrial cancer in 
some studies by half (36). Cigarette smoking reduces the risk of endometrial 
carcinoma. 
Clinical features 
The peak incidence of endometrial carcinoma is in postmenopausal 
women between 55 -65 yrs of age. Carcinoma of the endometrium is rare in 
women under the age of 40. It usually presents with irregular or post menopausal 
vaginal bleeding. 
Gross features 
The tumor may be seen as diffuse endometrial thickening or commonly 
as one or more multiple exophytic growths with a shaggy appearance. 
Sometimes it may be a polypoidal growth. Myometrial invasion is accompanied 
by enlargement of the uterus. The cervix is involved in approximately 20% of 
cases.  
Microscopic features 
 Endometrioid carcinoma demonstrates a glandular pattern resembling 
normal proliferative endometrium. The grading is based on the microscopic 
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appearance of the amount of solid growth of the glandular component. The cells 
are larger than cells of normal endometrium, show varying degrees of 
pleomorphism and prominent nucleoli. The nuclear grade is determined by the 
degree of anisonucleosis, chromatin distribution and size of the nucleoli. 
Assessment of myometrial invasion is important for staging the tumor. In the 
majority of cases myometrial invasion is accompanied by a desmoplastic stroma 
and inflammatory response. Whereas, some low grade tumors infiltrate the 
myometrium without stromal response.  
The most recent revision of the FIGO (International Federation of 
Gynecology and Obstetrics) Staging System is given below. Grading of the 
tumor should be done (both architectural and nuclear grading) before classifying 
endometrial carcinoma using FIGO staging. 
International Federation of Gynaecology and Obstetrics Staging of 
Endometrial Cancer, 2009 (5) 
IA G123 Tumor limited to the inner half of myometrium 
IB G123 Tumor invasion into the outer half of myometrium 
II  G123  Tumor invades cervical stroma 
IIIA  G123  Tumor invades serosa and/or adnexa 
IIIB  G123  Vaginal and/or parametrial involvement 
IIIC1  G123  Metastases to pelvic lymph nodes 
IIIC2  G123  Metastases to paraaortic lymph nodes 
IVA  G123  Tumor invasion of bladder and/or bowel mucosa 
IVB  G123  Distant metastases including intraabdominal and/or 
inguinal lymph nodes 
  
 
 
 
 
 
 
 
METHODOLOGY 
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METHODOLOGY 
The prospective study was conducted at the Department of pathology at 
Karpaga Vinayaga Institute of Medical Sciences, Chinna Kolambakkam for a 
period of two years from August 2013 to September 2015. The study was 
approved by the Institutional Ethics Committee. The study was conducted on 
150 consecutive endometrial samples obtained by dilatation and curettage.  
Patients presenting to the gynaecology OPD with symptoms of abnormal 
uterine bleeding were selected. Complete history including drug history was 
taken. A complete general examination was done. Routine investigations like 
complete blood count, bleeding time, clotting time and Chest X-ray were done. 
Ultrasound abdomen and pelvis was performed by an experienced sonologist. 
IMMUNOHISTOCHEMISTRY 
Endometrial samples of 41 premenopausal women which were 
histopathologically diagnosed as proliferative, simple hyperplasia, complex 
hyperplasia, atypical hyperplasia and endometrial adenocarcinoma were 
analysed immunohistochemically for ER and PR expression.  
INCLUSION CRITERIA 
Patients with abnormal vaginal bleeding aged > 18 years who presented 
to the gynaecology department were included. 
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EXCLUSION CRITERIA 
Patients with systemic diseases, genital tuberculosis, IUCD in situ, 
incomplete history, inadequate samples, bleeding and coagulation defects, 
pregnancy complications like abortion, molar pregnancy, ectopic pregnancy and 
patients on antiplatelet drugs were excluded.  
COLLECTION OF SPECIMEN 
Patients recruited into the study were admitted and endometrial curettage 
was performed by a gynaecologist. The tissue samples were received in 10% 
formalin and sent to the pathology department. After routine processing, tissue 
sections of 4-6 microns were cut and stained with eosin and haematoxylin. The 
slides were seen under the light microscope by pathologists and studied for their 
histomorphological patterns. Four micron thick representative tissue sections 
were immunohistochemically stained for ER and PR using a combination of 
HRP and pressure cooker antigen retrieval was used (tris-EDTA buffer- pH 6) 
and analysed for positivity of receptors in the glandular epithelium. 
STATISTICAL METHODS 
Data were entered in Microsoft excel and managed using SPSS software 
version 16. Patients were categorised into three age groups, namely reproductive 
age group (18-40 yrs.), perimenopausal age group (41-50 yrs.) and post-
menopausal age group (>50 yrs.). Analysis was done in the form of percentages 
and proportions and represented in tables and graphs.  
  
 
 
 
 
 
RESULTS 
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RESULTS 
A total of 150 patients underwent diagnostic D&C for AUB during the study 
period and the curettage was submitted for histopathological examination. The 
age of the patients studied were categorized into three groups, namely 
reproductive, perimenopausal and post-menopausal. Patients with AUB ranged 
from 23 to 65 years with a mean age of 42.6 years and a median age of 42 years. 
Maximum patients (49 %) with abnormal uterine bleeding presented in age group 
41-50 years closely followed by 42% in the reproductive (18-40 years) age 
group. The menopausal age group constituted 13% of patients.  
Table-1. Age group of patients presenting with AUB 
Age group (years) Total  % 
18 - 40 years (reproductive)  63 42 
41 - 50 years (perimenopausal)  74 49 
> 50 years (postmenopausal)  13 9 
Total  150 100 
 
 
 
 
63
74
13
Graph-1. Age group of patients presenting with AUB
18 - 40 years (reproductive)
41 - 50 years (perimenopausal)
> 50 years (postmenopausal)
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Table-2. Parity of patients presenting with AUB 
S.№ Parity Number Percentage (%) 
1 Nulliparous 1 0.7 
2 Low parity (P1 – P2) 95 63.3 
3 Multiparous (P3 – P4) 54 36 
 Total 150 100 
 
 
Of these 150 patients, 63.3% of patients are of low parity (P1 or P2), 36% of 
patients were multiparous and only one patient (0.7 %) was nulliparous. 
  
Nulliparous
0.7%
Low parity (P1 – P2)
63.3%
Multiparous (P3 – P4)
36.0%
Graph-2. Parity of patients presenting with   AUB
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Table-3. Pattern of bleeding in patients presenting with AUB 
 
 
 
 
 
 
The most common complaint was menorrhagia (58.7%), followed by 
metrorrhagia (23.3%). Meno-metrorrhagia constituted 12% and postmenopausal 
bleeding is seen in 8.7% of patients. Polymenorrhea was rare, seen in 2 (1.3%) 
patients.  
  
58.7%
23.3%
8.0%
1.3%
8.7% Graph-3. Pattern of bleeding in patients presenting 
with AUB
Menorrhagia
Metrorrhagia
Meno-metrorrhagia
Polymenorrhea
Post-menopausal bleeding
S.№ Pattern of bleeding number % 
1 Menorrhagia 88 58.7 
2 Metrorrhagia 35 23.3 
3 Meno-metrorrhagia 12 8.0 
4 Polymenorrhea 2 1.3 
5 Post-menopausal bleeding 13 8.7 
 Total 150 100.0 
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Table-4. Pattern of bleeding in patients presenting with AUB 
S.№ Pattern of bleeding 18 - 40 41 - 50 > 50 Total % 
1 Menorrhagia 45 43 0 88 58.7 
2 Metrorrhagia 13 22 0 35 23.3 
3 Meno-metrorrhagia 5 7 0 12 8.0 
4 Polymenorrhea 0 2 0 2 1.3 
5 Post-menopausal bleeding 0 0 13 13 8.7 
 Total 63 74 13 150 100 
 
 
Age specific analysis of the pattern of bleeding revealed that menorrhagia is 
the most common complaint in both the reproductive and perimenopausal age 
group followed by metrorrhagia. The second most common complaint in the 
reproductive and post-menopausal age groups were metrorrhagia. 
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Graph-4. Pattern of bleeding in patients presenting with 
AUB
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Post-menopausal bleeding
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Table-5. Distribution of cases of AUB according to cause according to age 
group 
Cause of AUB 18 - 40 41 - 50 > 50 Total % 
Functional causes 31 41 8 80 53 
Organic lesions 32 33 5 70 47 
Functional/ Organic 0.96 1.24 1.6 1.14 - 
Total 63 74 13 150 100 
 
 
 
Evaluation of the endometrium revealed various patterns on histopathology 
(Table-6). Functional causes accounted for slightly more than half of the causes 
(53%). In the present study, the proportion of functional to organic causes 
increase as age increases (0.96 in reproductive age; 1.24 in perimenopausal and 
1.6 in post-menopausal women). 
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cause according to age group
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Table-6. Frequency of Various Histopathological Patterns of Endometrial 
Curettings in Abnormal Uterine Bleeding 
S.№ HISTOPATHOLOGICAL DIAGNOSIS Total % 
1 Simple hyperplasia 32 21.33 
2 Proliferative pattern 31 20.67 
3 Secretory pattern 21 14.00 
4 Complex hyperplasia 14 9.33 
5 Disordered proliferative endometrium 10 6.67 
6 Atrophic endometrium 9 6.00 
7 Endometrial polyp 6 4.00 
8 Menstrual phase 6 4.00 
9 Atypical hyperplasia 5 3.33 
10 Secretory hyperplasia 4 2.67 
11 Endometrial adenocarcinoma 3 2.00 
12 Chronic endometritis 2 1.33 
13 Arias stella effect 1 0.67 
14 Endometrial metaplasia 1 0.67 
15 Granulomatous TB 1 0.67 
16 Hormonal changes 1 0.67 
17 Irregular shedding 1 0.67 
18 Mixed pattern 1 0.67 
19 
Squamous cell carcinoma infiltrating 
endometrium 
1 0.67 
  Total 150 100 
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Overall, the commonest histopathological diagnosis was simple hyperplasia 
21.3%), followed by the proliferative pattern (20.6%), secretory pattern (14%) 
complex hyperplasia (9%), disordered proliferative endometrium (6.6%), 
atrophic endometrium (6%), endometrial polyp (4%), menstrual phase (4%), 
atypical hyperplasia (3.3%), secretory hyperplasia (2.67%) and endometrial 
adenocarcinoma (2%).  
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Table-7. Histopathological patterns according to age group 
S.№
  
HISTOPATHOLOGIC
AL DIAGNOSIS  
Age group ( years) Total
  
%  
18 - 40 41 - 50 > 50 
1 Simple hyperplasia 18 (28.6%) 12 (16.2%) 2 (15.4%) 32 21.33 
2 Proliferative pattern 14 (22.2%) 17 (23%) 0 31 20.67 
3 Secretory pattern 10 (15.9%) 11 (14.9%) 0 21 14.00 
4 Complex hyperplasia 6 (9.5%) 8 (10.8%) 0 14 9.33 
5 
Disordered proliferative 
endometrium 
4 (6.3%) 5 (6.8%) 1 (7.7%) 10 6.67 
6 Atrophic endometrium 0 2 (2.7%) 7 (53.8%) 9 6.00 
7 Endometrial polyp 3(4.8%) 3 (4.1%) 0 6 4.00 
8 Menstrual phase 3 (4.8%) 3 (4.1%) 0 6 4.00 
9 Atypical hyperplasia 2 (3.2%) 2 (2.7%) 1 (7.7%) 5 3.33 
10 Secretory hyperplasia 2 (3.2%) 2 (2.7%) 0 4 2.67 
11 
Endometrial 
adenocarcinoma 
0 2 (2.7%) 1 (7.7%) 3 2.00 
12 Chronic endometritis 0 2 (2.7%) 0 2 1.33 
13 Arias stella effect 1 (1.6%) 0 0 1 0.67 
14 Endometrial metaplasia 0 1 (1.4%) 0 1 0.67 
15 Granulomatous TB 0 1 (1.4%) 0 1 0.67 
16 Hormonal changes 0 1 (1.4%) 0 1 0.67 
17 Irregular shedding 0 1 (1.4%) 0 1 0.67 
18 Mixed pattern 0 1 (1.4%) 0 1 0.67 
19 
Squamous cell carcinoma 
infiltrating endometrium 
0 0 1 1 0.67 
  Total 63 (100%) 74 (100%) 13 (100%) 150 100.00 
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In the reproductive age group, the commonest histopathological diagnosis 
was simple hyperplasia (28.6%), followed by the proliferative pattern (22.2%), 
secretory pattern (15.9%) complex hyperplasia (9.5%) and disordered 
proliferative endometrium (6.3%). 
In the perimenopausal age group, diagnoses were proliferative pattern (23%) 
followed by simple hyperplasia (16.2%), secretory pattern (14.9%), complex 
hyperplasia (10.8%) and disordered proliferative endometrium (6.8%). 
The commonest histopathological diagnosis in patients presenting with post-
menopausal bleeding was atrophic endometrium (53.8%) followed by simple 
hyperplasia (15.4%), disordered proliferative endometrium (7.7%), endometrial 
adenocarcinoma (7.7%), atypical hyperplasia (7.7%) and squamous cell 
carcinoma infiltrating endometrium (7.7%).  
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Table-8. Abnormal uterine bleeding due to non-organic causes 
S.№ 
HISTOPATHOLOGICAL 
DIAGNOSIS 
Age group ( years) 
Total % 
18 - 40 41 - 50 > 50 
1 Proliferative pattern 14 17 0 31 38.75 
2 Secretory pattern 10 11 0 21 26.25 
3 
Disordered proliferative 
endometrium 
4 5 1 10 12.50 
4 Atrophic endometrium 0 2 7 9 11.25 
5 Menstrual phase 3 3 0 6 7.50 
6 Hormonal changes 0 1 0 1 1.25 
7 Irregular shedding 0 1 0 1 1.25 
8 Mixed pattern 0 1 0 1 1.25 
 Total 31 41 8 80 100.00 
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The non-organic causes (in all age groups) in decreasing order of frequency 
is proliferative pattern (38.75%), secretory pattern (26.25%), disordered 
proliferative endometrium (12.50%), atrophic endometrium (11.25%), menstrual 
phase (7.5%), hormonal changes (1.25%), irregular shedding (1.25%), and 
mixed pattern (1.25%). 
Table-9. Abnormal uterine bleeding due to Organic causes 
 
S. 
№ 
HISTOPATHOLOGICAL 
DIAGNOSIS 
Age group ( years) 
Total % 
18 - 40 41 - 50 > 50 
1 Simple hyperplasia 18 (56.3%) 12 (36.4%) 2 (40%) 32 45.71 
2 Complex hyperplasia 6 (18.8%) 8 (24.2%) 0 14 20.00 
3 Endometrial polyp 3 (9.4%) 3 (9.1%) 0 6 8.57 
4 Atypical hyperplasia 2 (6.3%) 2 (6.1%) 1 (20%) 5 7.14 
5 Secretory hyperplasia 2 (6.3%) 2 (6.1%) 0 4 5.71 
6 Endometrial adenocarcinoma 0 2 (6.1%) 1 (20%) 3 4.29 
7 Chronic endometritis 0 2 (6.1%) 0 2 2.86 
8 Arias stella effect 1 (3.1%) 0 0 1 1.43 
9 Endometrial metaplasia 0 1 (3%) 0 1 1.43 
10 Granulomatous TB 0 1 (3%) 0 1 1.43 
11 
Squamous cell carcinoma 
infiltrating endometrium 
0 0 1 (20%) 1 
1.43 
 
Total 32 33 5 70 100.00 
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The organic causes of abnormal uterine bleeding in this series diagnosed by 
histopathological examination of D&C specimens in decreasing order of 
frequency are simple hyperplasia (45.7%), complex hyperplasia (20%), polyps 
(8.5%), atypical hyperplasia (7.1%), secretory hyperplasia (5.7%), endometrial 
adenocarcinoma (4.2%), chronic endometritis (2.8%), Arias stella effect (1.4%), 
endometrial metaplasia (1.4%), granulomatous TB (1.4%) and squamous cell 
carcinoma infiltrating endometrium (1.4%). 
 Simple hyperplasia (56.3%) was the commonest organic cause in the 
reproductive age group followed by complex hyperplasia (18.8%), endometrial 
polyps (9.4%), secretory hyperplasia (6.3%), atypical hyperplasia (6.3%) and 
Arias stella effect (3.1%). 
 Simple hyperplasia (36.4%) was the commonest organic cause in the 
perimenopausal age group followed by complex hyperplasia (24.2%), polyps 
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(9.1%), secretory hyperplasia (6.1%), endometrial adenocarcinoma (6.1%), 
atypical hyperplasia (6.1%), chronic endometritis (6.1%), endometrial 
metaplasia (3%) and granulomatous TB (3%). 
 In the post-menopausal age group, there were two cases of simple 
hyperplasia and one case each in endometrial adenocarcinoma, atypical 
hyperplasia and squamous cell carcinoma infiltrating endometrium. 
Table-10. Correlation between the pattern of bleeding and 
histopathological diagnosis 
Pattern of 
bleeding 
HISTOPATHOLOGICAL DIAGNOSIS NUMBER 
OF CASES 
% 
MR 
Proliferative pattern 24 27.3 
Secretory pattern 15 17.0 
Simple hyperplasia 14 15.9 
Complex hyperplasia 10 11.4 
Disordered proliferative endometrium 6 6.8 
Menstrual phase 5 5.7 
Endometrial polyp 5 5.7 
Secretory hyperplasia 2 2.3 
Atypical hyperplasia 2 2.3 
Irregular shedding 1 1.1 
Granulomatous TB 1 1.1 
Endometrial metaplasia 1 1.1 
Atrophic endometrium 1 1.1 
Arias stella effect 1 1.1 
Total 88 100 
MTR 
Simple hyperplasia 11 31.4 
Proliferative pattern 5 14.3 
Secretory pattern 5 14.3 
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Complex hyperplasia 4 11.4 
Disordered proliferative endometrium 2 5.7 
Secretory hyperplasia 2 5.7 
Endometrial adenocarcinoma 2 5.7 
Endometrial polyp 1 2.9 
Atypical hyperplasia 1 2.9 
Chronic endometritis 1 2.9 
Mixed pattern 1 2.9 
Total 35 100 
MMTR 
Simple hyperplasia 3 25.00 
Proliferative pattern 2 16.67 
Secretory pattern 1 8.33 
Disordered proliferative endometrium 1 8.33 
Atrophic endometrium 1 8.33 
Menstrual phase 1 8.33 
Atypical hyperplasia 1 8.33 
Chronic endometritis 1 8.33 
Hormonal changes 1 8.33 
Total 12 100 
PMR 
Simple hyperplasia 2 100 
Total 2 100 
PMB 
Atrophic endometrium 7 53.8 
Simple hyperplasia 2 15.4 
Disordered proliferative endometrium 1 7.7 
Endometrial adenocarcinoma 1 7.7 
Atypical hyperplasia 1 7.7 
Squamous cell carcinoma infiltrating 
endometrium 
1 7.7 
Total 13 100 
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The histological diagnosis in patients presenting with menorrhagia in 
decreasing order of frequency are proliferative pattern (27.3%), secretory pattern 
(17%), simple hyperplasia (15.9%) , complex hyperplasia (11.4%), disordered 
proliferative endometrium (6.8%), endometrial polyp (5.7%), menstrual phase 
endometrium (5.7%) and so on. 
The histological findings in patients presenting with metrorrhagia are simple 
hyperplasia (31.4%), proliferative pattern (14.3%), secretory pattern (14.3%), 
complex hyperplasia (11.4%), disordered proliferative endometrium (5.7%), 
secretory hyperplasia (5.7%), endometrial adenocarcinoma (5.7%) and so on. 
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Table-11. Correlation between the pattern of bleeding and causes 
S.№ Pattern of bleeding Organic Non-organic 
1 Menorrhagia 36 52 
2 Metrorrhagia 22 13 
3 Meno-metrorrhagia 5 7 
4 Polymenorrhea 2 0 
5 Post-menopausal bleeding 5 8 
 Total 70 80 
 
 
In abnormal uterine bleeding due to both organic and non-organic causes, 
menorrhagia was the commonest pattern of bleeding followed by metrorrhagia. 
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Table-12. Different types of endometrial hyperplasia 
S.№ Type № of cases % 
1 Simple hyperplasia 32 62.7 
2 Complex hyperplasia 14 27.5 
3 Atypical hyperplasia 5 9.8 
  Total 51 100 
 
 
  
Among the various types of hyperplasias (total= 51), simple hyperplasia 
(62.7%) was the commonest type followed by complex hyperplasia (27.5%) and 
atypical hyperplasia (9.8%). 
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Table-13. Different types of endometrial hyperplasia according to the age 
group 
S.№ Type 18 - 40 41 - 50 > 50 Total % 
1 Simple hyperplasia 18 12 2 32 62.7 
2 Complex hyperplasia 6 8 0 14 27.5 
3 Atypical hyperplasia 2 2 1 5 9.8 
  Total 26 22 3 51 100 
 
 
Age-wise analysis of the distribution of hyperplasias revealed that simple 
hyperplasia was the commonest type of hyperplasia seen in all the three age 
groups followed by complex hyperplasia and atypical hyperplasia. 
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Table-14. Correlation between endometrial thickness and histology 
S.№ Histology 
Endometrial thickness (mm) 
Total 
<5 5-10 11-15 16-20 
1 Proliferative pattern 1 24 6 0 31 
2 Secretory pattern 1 17 2 0 20 
3 Hyperplasia 0 26 22 3 51 
4 Atrophic endometrium 4 5 0 0 9 
5 Others 0 23 6 1 30 
  Total 6 95 36 4 141 
 
 
 Correlation between endometrial thickness and the histological pattern 
revealed that most cases of hyperplasia have an endometrial thickness between 
5 and 15 mm (with 3 case having a thickness > 15 mm), whereas all cases of 
atrophic endometrium have endometrial thickness < 10 mm. Thus the 
histological diagnosis correlated well with the ultrasound findings.  
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Table-15. Immunohistochemical staining of ER and PR in the glandular 
epithelium of perimenopausal women presenting with AUB 
Immunostaining ER PR 
Endometrial 
changes 
Positive Negative Positive Negative 
 N % N % N % N % 
Non-malignant 32 94.1 7 100 31 96.9 8 88.9 
Malignant 2 5.9 0 0 1 3.1 1 11.1 
Total 34 100 7 100 32 100 9 100 
 Immunohistochemical staining was done in perimenopausal women with 
histological diagnosis of proliferative endometrium, all types of hyperplasia and 
endometrial adenocarcinoma. Analysis of the results of immunostaining revealed 
that both the cases of endometrial adenocarcinoma were positive for both ER 
and PR, whereas in the remaining 39 cases of non-malignant endometrium 32 
(94.1%) cases were positive for ER and 31 (96.9%) cases were positive for PR. 
 
Table-16. Correlation between immunostaining for ER, PR and 
histopathological findings 
Immunostaining ER PR 
Histopathologic finding N 
% of 
positive 
cases 
N 
% of 
positive 
cases 
Proliferative endometrium 14/17 82.35 13/17 76.47 
Simple Hyperplasia 10/12 83.33 9/12 75.00 
Complex Hyperplasia 6/8 75.00 7/8 87.50 
Atypical hyperplasia 2/2 100.00 2/2 100.00 
Endometrial adenocarcinoma 2/2 100.00 1/2 50.00 
Total 33/41 80.49 32/41 78.05 
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All cases of atypical hyperplasia and endometrial carcinoma were positive 
for both ER and PR. Among proliferative endometrium, 82.35% were positive 
for ER and 76.47% were positive for PR. In simple hyperplasia, the percentage 
of cases showing positivity for ER and PR are respectively 83.33% and 75%. In 
complex hyperplasia, the percentage of cases positive for ER and PR are 
respectively 75% and 87.5%. 
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Table-17. Index of ER and PR Positivity in Glandular Epithelium of 
Proliferative Endometrium, Hyperplasic Endometrium and Endometrial 
Carcinoma 
S.№ 
Histopathological 
diagnosis 
ER PR 
N 
PI-ER 
% 
P N 
PI- PR 
% 
P 
1 Proliferative  14 91.64 
<0.001 
13 94.38 
<0.001 
2 Simple hyperplasia 10 60.20 9 65.33 
3 
Complex 
Hyperplasia 
6 58.33 7 60.71 
4 Atypical hyperplasia 2 51.50  2 53.00  
5 
Endometrial 
Adenocarcinoma 
2 27.50 
 
1 27.00 
 
* PI- percentage index 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
Proliferative Simple hyperplasia Complex
Hyperplasia
Atypical hyperplasia Endometrial
Adenocarcinoma
Graph-17. Index of ER and PR Positivity in Glandular 
Epithelium of Proliferative Endometrium, Hyperplasic 
Endometrium and Endometrial Carcinoma
ER PR
66 
 
 
 
 
The analysis of the percentage of positively stained cells was done by 
counting the number of positively stained cells divided by the total number of 
cells counted. The percentages were calculated for each case and the mean of the 
percentages calculated for all cases in each category of diagnosis. It is observed 
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that mean PI values to ER were highest for proliferative endometrium (91.64%) 
followed by simple hyperplasia (60.20%), complex hyperplasia (58.33%), 
atypical hyperplasia (51.5%) and endometrial carcinoma (27%). Similar findings 
were seen with respect to mean PI values to PR positivity with the highest values 
for proliferative pattern (94.38%) and lowest mean PI value for endometrial 
carcinoma (27%). 
One-way analysis of variance is used to determine whether there are any 
significant differences between the mean PI values for ER and PR of the three 
common categories that is the proliferative pattern, simple hyperplasia and 
complex hyperplasia. Atypical hyperplasia and endometrial carcinoma were not 
included in the analysis because of small sample size. The statistical analysis 
revealed that the differences between the mean PI values of the three common 
categories are highly significant (p <0.001). 
  
 
 
 
 
 
 
FIGURES 
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Figure-1A. Proliferative Pattern 10x magnification 
 
 
Figure-1B. Proliferative Pattern photomicrograph 40x magnification 
showing widely spaced tubular glands, pseudostratification and 
mitosis 
ii 
 
 
 
Figure-2A Secretory phase scanner view to show tortuosity of glands. 
 
 
 
Figure-2B. Secretory phase-photomicrograph under 40x showing 
tubular glands with subnuclear vacuolation. 
iii 
 
 
 
Figure-3. Menstrual phase photomicrograph under 10x 
magnification showing broken endometrial glands and haemorrhage 
 
 
 
Figure-4. Atrophic endometrium 
iv 
 
 
Figure-5A. Polyp -photomicrograph under the scanner shows 
polypoidal fragments with lining epithelium, focal glandular dilation 
and crowding and thick walled blood vessels. 
 
 
Figure-5B. Polyp -under 40x magnification thick walled blood vessels 
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Figure-6A. Granulomatous TB scanner view, showing granulomas 
composed of giant cells, epitheloid cell and necrosis. 
 
 
Figure-6B. Granulomatous TB 40 x showing –granuloma with the 
typical langhans giant cell. 
vi 
 
 
 
 
 
Figure-7. DOP photomicrograph showing occasional cystically 
dilated glands admixed with short tubular glands. 
 
 
vii 
 
 
 
Figure-8. Simple Hyperplasia under 40 x magnification showing 
minimally crowded glands with outpouchings. 
 
 
 
 
Figure-9. Complex Hyperplasia without atypia-back to back glands 
with complex branching infoldings and minimal intervening stroma 
viii 
 
 
Figure-10A. Scanner showing complex hyperplasia with atypia. 
 
 
 
Figure-10B. Complex hyperplasia with atypia 10x magnification 
glands are back to back with complex branching and nuclear atypia. 
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Figure-11. Adenocarcinoma-40x magnification complex branching 
forming labyrinthine pattern with no intervening stroma. 
 
 
 
Figure-12. Endometrial adenocarcinoma – villoglandular pattern 
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MIMICKERS OF PRE-MALIGNANT AND MALIGNANT 
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Figure-13. Arias Stella Reaction 
 
 
Figure-14. Secretory Exhaustion 
xi 
 
 
 
 
Figure-15. ER of proliferative endometrium-40x magnification strong 
and intense nuclear positivity. 
 
 
 
 
 
Figure-16. PR of proliferative endometrium-40x magnification strong 
and intense nuclear positivity. 
 
xii 
 
 
 
Figure-17. ER expression of simple hyperplasia-moderate nuclear 
positivity 
 
 
 
 
 
Figure-18. PR expression of simple hyperplasia-moderate nuclear 
positivity 
xiii 
 
 
 
 
Figure-19. ER expression of endometrial adenocarcinoma showing 
weak positivity 
 
 
 
Figure-20. PR expression of endometrial adenocarcinoma showing 
weak positivity  
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DISCUSSION 
Any vaginal bleeding not satisfying the criteria for normal menstruation 
is called as abnormal uterine bleeding. It is caused by a wide variety of diseases 
of the reproductive system as well as non-gynaecologic causes. Organic 
etiologies of AUB include diseases of the reproductive tract, iatrogenic and 
systemic causes. Dysfunctional uterine bleeding can be diagnosed only after all 
the organic causes of AUB have been excluded. 
The highest incidence of AUB in our study was in the perimenopausal age 
group (49%) followed by the reproductive age group (42%). This is also the 
commonest age group affected in most of the studies like Soleymani E et al (37), 
Shwetha Agrawal et al (38), Jagadale Kunda et al (39). 
The most common presenting complaint in this study is menorrhagia 
(58.7%) followed by metrorrhagia (23.3%). Menorrhagia is also the commonest 
complaint in many studies like Sadia Khanl et al  (40), Sajitha K et al (41), 
Shwetha Agrawal et al (38) and Jagadale Kunda et al (39). Metrorrhagia is the 
commonest complaint in studies like Bhatta S et al (42) and Naheed Moghal et 
al (43). Polymenorrhea is a rare complaint in our study, whereas it is the 
commonest complaint in Mariam abid et al (44). 
 AUB can be caused by organic or functional (non-organic) causes. In the 
most of the studies functional causes are common than organic causes. Likewise, 
functional causes are slightly more common (53%) than organic causes in this 
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study. This is comparable to findings in studies like Supriya sandeepa et al (45), 
Doraiswami saraswathi et al (8), Jagadale Kunda et al (39). In few studies like 
Nadia Adnan Ghani et al (46), Gerald Dafe Forae et al (47), Mariam abid et al 
(44)  and Smita S Patne et al (48), organic causes are more common than 
functional causes. 
Table-18. Comparative study of incidence of functional and organic causes 
S.№ Study 
Organic 
(%) 
Non-Organic/ 
functional (%) 
1. Sadia Khan et al (40) 14 86 
2. Soleymani E et al (37) 18.6 81.4 
3. S. Vaidya et al (49) 19 81 
4. Jagadale Kunda et al (39) 45 55 
5. Supriya sandeepa et al (45) 45.4 53.2 
6. Present study 47 53 
7. Doraiswami saraswathi et al (8) 48.66 51.34 
8. Gerald Dafe Forae et al (47) 57.2 42.8 
9. Mariam abid et al (44) 66 34 
10. Nadia Adnan Ghani et al (46) 61.8 33.5 
11. Smita S Patne et al (48) 75.72 24.28 
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Table-19. Comparative study of incidence of functional causes of AUB 
S.№ Study 
Normal cyclical 
pattern (PP + SP) 
DOP Atrophy 
1. Sadia Khan et al  (40) 84 - 1 
2. Soleymani E et al (37) 81.4 15.4 - 
3. Saera Afghan et al (50) 76 - 0.6 
4 Shwetha Agrawal et al (38) 71.75 - - 
5. Pankaj Malukani et al (51) 71 -- 7 
6. Zeeba S. Jairajpuri et al (52) 53.91 5.7 1.1 
7. 
Mahmoud Mohammed 
Mahmoud et al (53)  
51.99 - 4.95 
8. Supriya sandeepa et al (45) 51.1 0.2 1.1 
9. Naheed Moghal et al (43) 49.33 5.02 1.31 
10. Layla S Abdullah et al (54) 46.6 8.7 3.1 
11. Jagadale Kunda et al (39) 44 - - 
12. Bhatta S et al (42) 42.62 6.56 7.38 
13. Gerald Dafe Forae et al (47) 42.4 - - 
14. S. Vaidya et al (49) 40.94 13.4 4.71 
15. Bhoomika dadhania et al (55) 36.66 2.66 - 
16. Present study 34.67 6.67 6 
17. Sarwat Ara et al (56) 34.16 - 4.34 
18. Mariam abid et al (44) 34 - 6.22 
19. Sajitha K et al (41) 28.9 12.2 5.12 
20. Doraiswami saraswathi et al (8) 28.36 20.53 2.44 
21. Smita S Patne et al (48)  24.28 - - 
22. Nadia Adnan Ghani et al (46) 23.44 0.68 0.68 
PP – proliferative phase; SP – secretory phase 
 Normal cyclical patterns, including proliferative and secretory patterns 
are the most common histopathological diagnoses seen in most of the studies. 
This phenomenon is also seen in this study. Both patterns together constitute 34% 
of cases in this study. Similar findings are present in Bhoomika dadhania et al 
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(55) and Sarwat Ara et al (56). Highest incidence of cyclical patterns is observed 
in Sadia Khan et al (40), Soleymani E et al (37) and Saera Afghan et al (50). 
Disordered proliferative endometrium is seen in 6.67% cases in our study. 
Maximum incidence of this finding (20.53%) is seen in Doraiswami saraswathi 
et al (8). It is also a common cause of DUB in Soleymani E et al (37), where it 
accounts for 15.3% cases. 
 Atrophic endometrium is rarely seen in women of the reproductive age 
group. It is seen sometimes in perimenopausal women, but it is a common 
finding in post-menopausal women due to lack of ovarian estrogen. It’s 
incidence in the present study is 6%, which is almost similar to that observed in 
Mariam abid et al (44) and Sajitha K et al (41). In the present study 7/9 cases of 
atrophy were seen in women >50 years and 2/9 cases were seen in women aged 
41-50 yrs. 
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Table-20. Comparative study of the incidence of hyperplasia in AUB 
S.№ Study 
Hyperplasia 
(% of total 
causes) 
SH CH 
Atypic
al 
N 
1. Smita S Patne et al (48) 41.90 - - - 88 
2. Present study 33 62.7 27.5 9.8 51 
3. Sarwat Ara et al (56) 27.94 33.33 53.33 13.33 45 
4. Nadia Adnan Ghani et al (46) 26.89 100 0 0 39 
5. Bhoomika dadhania et al (55) 26.66 45 55 0 40 
6. Sajitha K et al (41) 25 - - - 39 
7. 
Mahmoud Mohammed 
Mahmoud et al (53) 
23.23 57.4 28.7 13.9 122 
8. Jagadale Kunda et al (39) 22 100 0 0 22 
9. Pankaj Malukani et al (51) 22 68.18 27.27 4.55 88 
10. Bhatta S et al (42) 18.03 100 0 0 22 
11. Supriya sandeepa et al (45) 17.4 - - - 98 
12. Gerald Dafe Forae et al (47) 17 71.79 12.82 15.38 39 
13. Shwetha Agrawal et al (38) 16.5 100 0 0 66 
14. Sadia Khan et al  (40) 12.6 50.79 22.22 26.98 63 
15. Naheed Moghal et al (43) 11.14 82.35 3.92 13.72 51 
16. S. Vaidya et al (49) 10.92 68.18 15.91 15.91 44 
17. Layla S Abdullah et al (54) 9.1 76.92 15.86 7.21 208 
18. Doraiswami saraswathi et al (8) 6.11 - - - 25 
19. Zeeba S. Jairajpuri et al (52) 5.79 64.8 13.5 21.6 37 
20. Saera Afghan et al (50) 5.2 4.6 0.6   
21. Mariam abid et al (44) 5 - - 54 12 
22. Soleymani E et al (37) 2.5 - - - - 
 Hyperplasias constitute 33% of cases of AUB in our study. Simple 
hyperplasia is present in 21.33% cases in this study. A similar incidence of 
hyperplasia is found in studies like Sarwat Ara et al (56), Nadia Adnan Ghani et 
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al (46) and Bhoomika dadhania et al (55). Hyperplasia ranks second only to 
normal cyclical patterns as the cause of AUB in most of the studies. In the present 
study also hyperplasia is the second common cause of AUB. 
The older terminologies like cystoglandular hyperplasia and adenomatous 
hyperplasia were used in some of the studies. These were replaced my newer 
terminologies like simple, complex and atypical hyperplasia in recent studies. 
Comparative analysis of the incidence of hyperplasias in various studies reveal 
that hyperplasia is a common organic cause of AUB. The highest incidence of 
hyperplasia is reported in Smita S Patne et al (48) (41.9%), where it was the 
commonest cause of AUB (common than normal physiological changes). Zeeba 
S. Jairajpuri et al (52), Saera Afghan et al (50), Mariam abid et al (44) and 
Soleymani E et al (37) reported a low incidence of hyperplasia. Moderate to 
heavy vaginal bleeding is seen in women with hyperplasia, whereas women with 
atrophic endometrium may have only spotting. 
The overall risk of progression of hyperplasia to cancer is 5-10%. The risk 
of progression of simple hyperplasia, complex hyperplasia, simple hyperplasia 
with atypia and complex hyperplasia with atypia to carcinoma are respectively 
1%, 3%, 8% and 29% (57).
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Table-21. Comparative study of the incidence of common organic causes of 
AUB 
S.№ Study 
Pregnancy 
complication
s 
Endomet
ritis 
Polyp 
Maligna
ncy 
1. Present study - 1.33 4 2 
2. Sadia Khan et al  (40) - 0.4 0.6 0.4 
3. Soleymani E et al (37) - -  0.7 
4 Layla S Abdullah et al (54) - 5.8 9.9 1.8 
5. Mariam abid et al (44) - 12 14 2 
6. Sajitha K et al (41) - 0.64 5.12 4.5 
7. Nadia Adnan Ghani et al (46) 20.68 3.44 8.96 1.31 
8. Supriya sandeepa et al (45)  24.1 0.7  1.1 
9. Shwetha Agrawal et al (38) - - - 4.5 
10. Zeeba S. Jairajpuri et al (52) 15.36 6.1 1.72 0.4 
11. Jagadale Kunda et al (39) 18 - 1 4 
12. Bhoomika dadhania et al (55) - 2 - 2.66 
13. Sarwat Ara et al (56) 16.15 6.21 4.34 1.86 
14. Gerald Dafe Forae et al (47) 27.7 1.3 3.1 3.4 
15. Doraiswami saraswathi et al (8) 22.74 4.15 11.24 4.4 
16. Bhatta S et al (42) - 6.56 2.46 5.74 
17. Naheed Moghal et al (43) - 3.28 6.33 0.44 
18. Saera Afghan et al (50)    0.6 
19. Smita S Patne et al (48) 13.8 7.14 5.71 2.38 
20. 
Mahmoud Mohammed Mahmoud 
et al (53) 
- 3.8 4 2.66 
21. S. Vaidya et al (49)  - 3.23 1.24 2.48 
22. Pankaj Malukani et al (51) - - - - 
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Complications of pregnancy are observed as a common cause of abnormal 
uterine bleeding in some studies like Nadia Adnan Ghani et al (46), Supriya 
sandeepa et al (45), Zeeba S. Jairajpuri et al (52), Sarwat Ara et al (56), Gerald 
Dafe Forae et al (47) and Doraiswami saraswathi et al (8). In fact, pregnancy 
complications was the commonest cause of AUB in Gerald Dafe Forae et al (47). 
Hence, this cause should be kept in mind when evaluating AUB in women of the 
reproductive age group. These patients should be investigated with urine 
gavindex test for pregnancy (58). 
 The incidence of endometritis in the present study is 1.33%. A high 
incidence of endometritis is noted in Zeeba S. Jairajpuri et al (52), Sarwat Ara et 
al (56), Bhatta S et al (42) and Smita S Patne et al (48). In the present study one 
case of tuberculous endometritis was noted. Doraiswami saraswathi et al (8) and 
Bhatta S et al (42) each reported one case of tuberculous endometritis. 
Endometritis was the commonest organic cause of AUB in Zeeba S. Jairajpuri et 
al (52). In this study, out of 39 cases of endometritis, three were tubercular in 
origin.  
Polyps are an important organic cause of AUB. The present study reported 
polyps in 4% of cases. Mariam abid et al (44) has the highest incidence of polyps 
(14% of cases). In this study, there is an increase in frequency of polyps with 
increasing age. In fact, polyps was the most common pathology in 
postmenopausal women in this study. Doraiswami saraswathi et al (8) reported 
the second highest incidence of polyps (11.24%). In this, most of the polyps were 
76 
 
seen in women aged 41-50 yrs. However, there is no greater propensity of polyps 
undergoing malignant change when compared with the adjacent normal 
endometrium (59). 
Malignancies are less common, but an important cause of abnormal 
uterine bleeding. In the present study, 3 cases of endometrial carcinoma were 
seen. Two cases were seen in perimenopausal women and one woman was 
postmenopausal. Among the malignancies, endometrial carcinoma (especially 
endometrioid type) was the commonest reported malignancy in most of the 
studies. Cases of malignant mixed mullerian tumor (MMMT), endometrial 
stromal sarcoma and adenosarcoma were rarely reported in some studies.  
Doraiswami saraswathi et al (8), Shwetha Agrawal et al (38) and Bhatta 
S et al (42) reported a high incidence of malignancies. Shwetha Agrawal et al 
(38) reported 18 cases of malignancies of the endometrium of which 14 were 
endometrial adenocarcinoma, 3 were endometrial stromal sarcoma and one case 
was MMMT. In Doraiswami saraswathi et al (8), one out the 18 cases of 
malignancy was malignant mixed mullerian tumor. Patients with MMMT are 
usually postmenopausal and commonly present with AUB. Nulliparity, increased 
BMI and chronic anovulation have been implicated as risk factors for 
endometrial carcinoma. 
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Table-22. Comparative study of results of present study with other studies 
PP – Proliferative endometrium; SP - secretory endometrium; SH- simple hyperplasia; CH – complex hyperplasia; DOP – disordered proliferative 
endometrium 
 Present study Sadia Khan  et al (40) Soleymani E et al  (37) Layla S Abdullah et al  (54) Mariam abid et al  (44) 
Number of cases 150 500 591 2295 241 
Type of bleeding AUB AUB AUB AUB AUB 
Common age group 41-50 (49%) 45-55 (42%) 41-50 (61.6%) ≥ 52 yrs Reproductive age group 
(49.3%) 
Common clinical  
Presentation 
Menorrhagia (58.7%) 
Metrorrhagia (23.3%) 
Menorrhagia (57.8%)   Polymenorrhea (30%) 
Irregular bleeding (26%) 
Common 
histopathological 
diagnosis 
Functional (53%) and 
organic (47%) 
1. Hyperplasia (33%) 
2. PP (20.67%) 
3. SP (14%) 
4. DOP (6.67%) 
5. Atrophy (6%) 
6. Polyps (4%) 
1. PP (46.4%) 
2. SP (37.6%) 
3. Hyperplasia 
(12.6%) 
1. Normal pathology 
(PP & SP) (81.4%) 
2. DOP (15.4%) 
3. Hyperplasia 
(2.5%) 
1. SP (24.9%) 
2. PP (21.7%) 
3. Polyp (9.9%) 
4. Hyperplasia (9.1%) 
5. DOP (8.7%) 
Organic (66%) and non-
organic (34%) 
1. Normal menstrual 
pattern (PP & SP) 
(34%) 
2. Hormonal imbalance 
pattern (27%) 
3. Polyp (14%) 
4. Endometritis (12%) 
5. Hyperplasia (5%) 
Hyperplasia 1. SH – 32 (62.7%) 
2. CH – 14 (27.5%) 
3. Atypical 
hyperplasia – 5 
(9.8%) 
1. Cystic hyperplasia 
without atypia 
(6.4%) 
2. Cystic hyperplasia 
with atypia (2.4%) 
3. Adenomatous 
hyperplasia without 
atypia (2.8%) 
4. Adenomatous 
hyperplasia with 
atypia (1.0%) 
 1. Simple cystic 
hyperplasia (7%) 
2. Complex hyperplasia 
without atypia (1.4%) 
3. Complex hyperplasia 
with atypia (0.7%) 
1. Hyperplasia with 
atypia (54%) 
2. Hyperplasia 
without atypia 
(46%) 
Frequency of 
malignancy 
Adenocarcinoma – 2% 
(n=3); Squamous cell 
carcinoma infiltrating 
endometrium (n=1) 
0.4% (n=2) 0.7% 1.8% (n=41); 28/ 41 in ≥ 52 
yrs. 
2% (n=5) 
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 Sajitha K et al (41) Nadia Adnan Ghani et al 
(46) 
Supriya sandeepa et al 
(45) 
Shwetha Agrawal et al 
(38) 
Zeeba S. Jairajpuri et al 
(52) 
Number of cases 156 (D&C/ 
Hysterectomy) 
152 564  400 638 
Type of bleeding AUB AUB AUB AUB AUB 
Common age group 46-55 (42.95%) 40-55 18-40 41-50 41-50 (35.89) 
Common clinical  
Presentation 
Menorrhagia (47%)   Menorrhagia (49%) 
Menometrorrhagia (22%) 
Menorrhagia (41%) 
Metrorrhagia (18%) 
Common 
histopathological 
diagnosis 
1. Hyperplasia (25%) 
2. SP (16.7%) 
3. PP (12.2%) 
4. DOP (12.2%) 
Organic (61.8%) & Non-
organic (33.5%) 
1. Hyperplasia (26.89%) 
2. Pregnancy related 
bleeding (20.68%) 
3. PP (15.86%) 
4. SP (7.58%) 
Organic (45.4%) & Non-
organic (53.2%) 
1. PP (27.7%) 
2. Pregnancy related 
lesions (24.1%) 
3. SP (23.4%) 
4. Hyperplasia 
(17.4%) 
Non-organic (71.75%) & 
Organic (28.25%) 
1. PP (55%) 
2. SP (16.75%) 
3. Hyperplasia (16.5%) 
4. Malignancy (4.5%) 
Functional – majority 
1. SP (28.99%) 
2. PP (24.92%) 
3. Pregnancy 
complications 
(15.36%) 
4. Endometritis (6.1%) 
5. Hyperplasia (5.79%) 
6. DOP (5.7%) 
Hyperplasia 1. SH (12.8%) 
2. SH with atypia 
(3.85%) 
3. CH (1.28%) 
4. CH with atypia 
(7.05%) 
All hyperplasias are SH 
without atypia 
  1. SH (64.8%) 
2. CH (13.5%) 
3. Atypical (21.6%) 
Frequency of 
malignancy 
4.5% (n=7) N= 2 (1.31%) 1.1% (n=6) Malignancies n=18 
 Endometrial Ca – 14 
 Endometrial stromal 
sarcoma – 3 
 Malignant mixed 
mullerian tumor – 1 
 
0.4% (n=3); all 
endometrioid with PMB 
 
PP – Proliferative endometrium; SP - secretory endometrium; SH- simple hyperplasia; CH – complex hyperplasia; DOP – disordered proliferative 
endometrium  
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 Jagadale Kunda et al (39) Bhoomika dadhania et al 
(55) 
Sarwat Ara et al (56) Gerald Dafe Forae et al 
(47) 
Doraiswami saraswathi et 
al (8) 
Number of cases 100 150 161 231 409 £ 
Type of bleeding AUB DUB* AUB AUB AUB 
Common age group 41-50 (31%) 41-50(40.66%) 36-50 (59.02%) 30-39 (31.2%) 41-50 (33.5%) 
Common clinical  
Presentation 
Menorrhagia (88%)  Menorrhagia (49.06%) 
Metrorrhagia (39.13%) 
  
Common 
histopathological 
diagnosis 
1. PP (29%) 
2. Hyperplasia (22%) 
3. Pregnancy related 
complications (18%) 
4. SP (15%) 
5. Polyp (1%) 
1. Hyperplasia (26.66%) 
2. PP (21.33%) 
3. SP (15.33%) 
1. Hyperplasia 
(27.94%) 
2. PP (21.74%) 
3. Pregnancy 
complications 
(16.15%) 
4. SP (12.42%) 
1. Products of 
conception (27.7%) 
2. PP (22.5%) 
3. SP (19.9%) 
4. Hyperplasia (17%) 
Isolated endometrial 
pathology on 409 cases 
1. Normal cyclical 
pattern (PP, SP & 
shedding) (28.36%) 
2. Complications of 
pregnancy (22.74%) 
3. DOP (20.53%) 
4. Polyp (11.24%) 
5. Hyperplasia (6.11%) 
Hyperplasia All hyperplasias are SH 
without atypia 
1. Adenomatous 
hyperplasia (13.33%) 
2. Simple cystic 
hyperplasia (12%) 
3. CH (1.33%) 
1. Adenomatous 
hyperplasia (14.91%) 
2. Cystic glandular 
hyperplasia (9.31%) 
3. Atypical hyperplasia 
(3.72%) 
1. SH (12.2%) 
2. CH (2.2%) 
3. Atypical (2.6%) 
 
Frequency of 
malignancy 
4% (n=4) 2.66% (n=4); all cases in 
patients > 50 yrs. 
1.86% (n=3) 3.4% (n=8) 
Endometrial Ca (n=4) 
MMMT≠ (n=3) 
Choriocarcinoma (n=1) 
4.4% (n=18) 
* Though the term DUB (which refers to the functional/non-organic cause of AUB) was used in the study, the organic causes like hyperplasia and adenocarcinoma 
are also included 
≠ Malignant mixed mullerian tumor 
£ Out of 620 cases (408 samples+ 212 hysterectomy), 211 cases with leiomyoma, adenomyosis and cervical pathology with or without endometrial lesions were 
excluded from the study. The remaining 409 patients with isolated endometrial pathology were included in the study 
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 Bhatta S et al (42) Naheed Moghal et al (43) Saera Afghan et al (50) Smita S Patne et al (48) Mahmoud Mohammed 
Mahmoud et al (53) 
Number of cases 122 458 150 210 525 
Type of bleeding AUB AUB AUB AUB AUB 
Common age group   31-40 (47.2%) 31-40 (33.8%) 41-50 
Common clinical  
Presentation 
Metrorrhagia (38.52%) 
Menorrhagia (30.32%) 
Metrorrhagia (48.04%) 
Menorrhagia (40.83%) 
Menorrhagia (34%) 
Polymenorrhagia (27%) 
Menorrhagia (42.85%) 
Metrorrhagia (28.09%) 
Menorrhagia (42.7%) 
Menometrorrhagia 
(18.9%) 
Common 
histopathological 
diagnosis 
1. PP (26.23%) 
2. Hyperplasia 
(18.03%) 
3. SP (16.39%) 
4. Atrophic (7.38%) 
 
1. SP (25.33%) 
2. PP (24%) 
3. Hyperplasia (11.14%) 
4. DOP (5.02%) 
1. Normal physiological 
changes (PP & SP) 
(76%) 
2. Hyperplasia (5.2%) 
3. Pill pattern (7.3%) 
1. Hyperplasia 
(41.90%) 
2. PP (24.28%) 
3. Pregnancy 
complications β 
(13.8%) 
4. Endometritis (7.14%) 
5. Polyp (5.71%) 
Organic (38.7%) and non-
organic (61.3%) 
1. PP (30.28%) 
2. Hyperplasia (23.23%) 
3. SP (21.71%) 
4. Atrophy (4.95%) 
5. Polyp (4%) 
6. Endometritis (3.8%) 
Hyperplasia All hyperplasia SH 
without atypia (18.03%) 
1. SH (n=42) 
2. CH (n=2) 
3. Atypical (n=7) 
1. Cystic hyperplasia 
(4.6%) 
2. Adenomatous 
hyperplasia (0.6%) 
 
 1. SH (57.4%) 
2. CH without atypia 
(28.7%) 
3. CH with atypia 
(13.9%) 
Frequency of 
malignancy 
5.74% (n=7) Endometrial Ca – 0.44% 
(n=2) 
Adenosarcoma – 0.21% 
(n=1) 
0.6% (n=1) 2.38% (n=5) 2.66% (n=14); all cases > 
50 yrs 
 
β Pregnancy related complications include products of conception, and partial and complete hydatiform mole 
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 S. Vaidya et al (49) Pankaj Malukani et al 
(51) 
Number of cases 403 400 
Type of bleeding AUB DUB µ 
Common age group 41-50 31-40 (48%) 
Common clinical  
Presentation 
 Menorrhagia (76.5%) 
Metrorrhagia (13.5%) 
Common 
histopathological 
diagnosis 
Functional (81%) and 
organic (19%) 
1. SP (22.58%) 
2. PP (18.36%) 
3. DOP (13.4%) 
4. Hyperplasia 
(10.92%) 
 
1. PP (39.75%) 
2. SP (31.25%) 
3. Hyperplasia (22%) 
4. Atrophy (7%) 
Hyperplasia 1. SH -30 (68.18%) 
2. CH -7 (15.91%) 
3. Atypical 
Hyperplasia -7 
(15.91%) 
1. SH – 60 (68.18%) 
2. CH – 24 (27.27%) 
3. Atypical hyperplasia 
– 4 (4.55%) 
 
Frequency of 
malignancy 
2.48% (n=10)  
 
µ Though the term DUB (which refers to the functional/non-organic cause of AUB) was used in the study, the organic cause like hyperplasia were also included. 
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Table-23. Comparative study of age-wise distribution of various histopathological diagnosis of present study with 
other studies 
S.№ Diagnosis Present study Layla S Abdullah et al (54) Mariam abid et al (44) 
  
18-40 
(63) 
41-50 
(74) 
>50 (13) 
Total 
(150) 
19-39 
(700) 
40-51 
(735) 
>51 
(860) 
Total 
(2295) 
12-39 
(119) 
40-50 
(77) 
>50 
(45) 
Total 
(241) 
1. Pr 
14 
(22.2%) 
17 (23%) 0 
31 
(20.67%) 
222 
(31.7%) 
113 
(15.4%) 
163 
(19%) 
498 
(21.7%) 61 
(51%) 
21 
(27.3%) 
0 
82 
(34%) 
2. Sec 
10 
(15.9%) 
11 
(14.9%) 
0 21 (14%) 
246 
(35%) 
122 
(16.6%) 
203 
(23.6%) 
571 
(24.9%) 
3. Hyperplasia 
26 
(41.3%) 
22 
(29.72%) 
3 
(23.07%) 
51 (34%) 
39 
(5.54%) 
94 
(12.84%) 
75 
(8.8%) 
208 
(9.1%) 
1 (1%) 
5 
(6.5%) 
6 
(13.2%) 
12 (5%) 
4. DOP 
4 
(6.3%) 
5 (6.8%) 1 (7.7%) 
10 
(6.67%) 
46 
(6.6%) 
85 
(11.6%) 
69 (8%) 
200 
(8.7%) 
0 0 0 0 
5. Polyp 
3 
(4.81%) 
3 (4.1%) 0 6 (4%) 
39 
(5.6%) 
75 
(10.2%) 
113 
(13.1%) 
227 
(9.9%) 
10 
(8.4%) 
8 
(10.4%) 
16 
(35.5%) 
34 
(14%) 
6. Endometritis 0 2 (2.7%) 0 
2 
(1.33%) 
44 
(6.3%) 
53 
(7.2%) 
37 
(4.3%) 
134 
(5.8%) 
21 
(18%) 
7 
(9.1%) 
0 
28 
(12%) 
7. Atrophy 0 2 (2.7%) 
7 
(53.81%) 
9 (6%) 0 
21 
(2.9%) 
49 
(5.7%) 
70 
(3.1%) 
0 0 
15 
(33.3%) 
15 
(6.2%) 
8. Carcinoma 0 2 (2.7%) 1 (7.7%) 3 (2%) 2 (0.3%) 
11 
(1.5%) 
28 
(3.3%) 
41 
(1.8%) 
0 
1 
(1.2%) 
4 (9%) 5 (2%) 
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Estrogen and progesterone are consistently produced by the ovaries. The 
endometrium is a highly sensitive indicator of the hypothalamic-pituitary-
ovarian axis. Both endometrial glandular and stromal cells have estrogen and 
progesterone receptors. The hormonal control is mediated by these receptors. 
Estradiol increases both ER and PR, while progesterone decreases both 
receptors.   
 The present study compared the immunohistochemical staining of ER and 
PR between non-malignant endometrium and malignant endometrium. The non-
malignant endometrium studied include proliferative pattern and all types of 
hyperplasia. This study showed that most of non-malignant endometrium 
showed positivity for estrogen receptors (94.1%) and progesterone receptors 
(96.9%). Quantitative analysis of the steroid hormone receptors (the number of 
positively stained cells divided by the total number of cells counted= percentage 
index) revealed that the mean of the Percentage Index of all the proliferative 
endometrium was the highest (91.64% for ER and 94.38% for PR) followed by 
simple hyperplasia, complex hyperplasia and atypical hyperplasia. It was also 
observed that the mean of the PI values for both ER and PR were the lowest for 
endometrial adenocarcinoma (27.5% for ER and 27% for PR). The mean values 
of PI for PR were slightly higher than that for ER. 
 Mylonas et al (60) compared the expression for ER and PR of normal 
human endometrium (proliferative and secretory) with that of malignant 
endometrium. The study revealed that ER and PR expression declined 
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significantly in the glandular epithelium when going from proliferative (high 
expression) to the secretory phase (low expression). The expression of the 
hormone receptors was lowest with adenocarcinoma. 
Daniela Ilie et al (61) compared the index to ER and PR positivity in the 
glandular epithelium of normal endometrium, hyperplastic endometrium and 
endometrial carcinoma. This study noted that the expression of ER and PR was 
predominant in the proliferative phase compared with the secretory phase. The 
ER and PR expression decreased in the hyperplastic and neoplastic endometrium 
compared with that of the proliferative phase. This study that among the 
hyperplasias, the mean PI for ER and PR was high in case of complex 
hyperplasia without atypia (mean PI for ER 72.3%; mean PI value for PR of 
78.5%) followed by atypical hyperplasia and simple hyperplasia. This is in 
contrast with our study which found that simple hyperplasia has high mean PI 
value (60.2% for ER; 65.33% for PR) followed by complex hyperplasia and 
atypical hyperplasia in that order. However, this study also found that 
endometrial carcinoma has the lowest value of mean PI which is similar to that 
observed in our study.  
Sahar Aly Daoud et al (62) compared the expression of ER and PR 
immunostaining in normal and hyperplastic endometrium with that of malignant 
endometrium. This is a qualitative study which studied the number of positive 
cases for ER and PR in each group. It found that among 28 cases of non-
malignant endometrium 22 (78.57%) were positive for ER and 19 (67.85%) were 
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positive for PR. Among 20 cases of endometrial carcinoma, 14 (70%) were 
positive for ER and 12 were positive for PR (60%).
  
 
 
 
 
CONCLUSION 
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CONCLUSION 
 
 
AUB is one of the common reasons for visit to the gynaecology outpatient 
department. 
The present study showed that the highest incidence of AUB is in the 
perimenopausal age group (41-50 years). 
Simple hyperplasia is the commonest histological diagnosis followed by 
the proliferative and secretory pattern. 
Immunohistochemistry reveals that ER and PR expression decreases 
progressively as we go from the proliferative pattern through hyperplasias to 
adenocarcinoma. 
  ER and PR expression in endometrial adenocarcinoma is of prognostic 
significance. PR positive tumors may be amenable to hormone therapy of women 
who wish to retain their fertility and non-surgical patients. 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURES 
 
  
ANNEXURES 
 
ANNEXURE A 
DATA COLLECTION FORM 
 
NAME :     DATE: 
AGE  : 
I.P.№  : 
WEIGHT : 
PARITY : 
CHIEF COMPLAINTS : 
 
PAST MEDICAL HISTORY : 
 
MENSTRUAL HISTORY : 
 
GROSS FINDINGS : 
 
HISTOPATHOLOGICAL FINDINGS: 
  
ANNEXURE B 
STAINING TECHNIQUE 
Hematoxylin and Eosin (H& E) 
Procedure 
1. Bring sections to water 
2. Stain with Harris Hematoxylin for 2-3 minutes 
3. Wash with running tap water 
4. Differentiate in 1% acid alcohol 
5. Wash and blue with running tap water 
6. Counter stain with aqueous eosin for 2 minutes 
7. Dehydrate with absolute alcohol (2-3 changes) 
8. Clear with 2-3 changes of xylene 
9. Mount using Dibutyl phthalate polystyrene xylene (Dpx) 
Results 
Nucleic acid – blue 
Cytoplasm – pink 
 
  
ANNEXURE C: FLOW CHART FOR IMMUNOHISTOCHEMISTRY
FIXATION 
To ensure the preservation of tissue architecture and cell 
morphology. The tissue is paced in the fixative for 8 hours. 10% 
formalin is used to ensure the preservation of tissue architecture 
and cell morphology 
GROSSING 
To identify and describe tissue 
morphology 
The tissue is examined and desired 
bit separated 
DEHYDRATION 
Transfer the tissue to 80% 
alcohol for 2 hours (second 
change) 
 
DEHYDRATION 
Transfer the tissue to Absolute 
alcohol for 2 hours (2 changes) 
 
DEHYDRATION 
Transfer the tissue to 70% 
alcohol for 2 hours (first 
change) 
Clearing 
Baked tissue is cleared by 
xylene for 10 minutes 
DEPARAFFINIZATION 
Dewaxing can be done by using EZ-
DEWAX or by conventional method 
BAKING 
The water between the section and the 
slide is removed by placing it in an 
oven or hot plate 
Rehydration 
Transfer the tissue to 
alcohol for 5 minutes 
Rehydration 
Transfer the tissue to 80% 
alcohol for 5 minutes 
 
Rehydration 
Transfer the tissue to 70% 
alcohol for 5 minutes 
 
Tissues are then placed in 
running tap water for 5 
minutes 
Clearing 
The dehydrated tissue is 
transferred to xylene for 2 
hours (2 changes) 
Infiltration 
Transfer the tissue to 
molten paraffin wax for 
4 hours   
Embedding 
A tissue in the molten paraffin 
is placed in mould with cassette 
and is filled with molten 
paraffin 
The paraffin is allowed to solidify. 
After solidification, the entire block 
with cassette is popped out from the 
mould 
Sectioning 
The block is placed in the microtome 
holder and sectioning is done. The ribbon 
of section is floated on warm water in a 
water bath 
On the water bath the sections are separated 
and placed on Poly-L-Lysine coated slides 
carefully 
APES (adhesive) 
 
  
Antigen retrieval 
Breaks the protein cross-links formed by formalin fixation and thereby uncover hidden antigenic sites 
ANTIGEN RETRIEVAL 
Perform antigen retrieval by using 
microwave oven/ pressure cooker 
Cool the slide to room 
temperature and wash 
the slides with distilled 
water 
PEROXIDE BLOCK 
Endogenous peroxidase activity is removed. 
Pour enough drops of 3% Hydrogen peroxide 
block over the tissue and incubate it in humidity 
chamber for 10 minutes 
Wash with PBS (3 
minute 3 changes) 
UV BLOCK  
Incubate for 10 minutes 
(no wash) 
PRIMARY ANTIBODY 
Add enough drops of 
primary antibody over the 
tissue and incubate for 30 
mts 
Wash with PBS (3 
minute 3 changes) 
Wash the slides with 
distilled water 
PRIMARY AMPLIFIER 
To enhance the process of primary 
antibody incubate for 20 minutes 
Wash with PBS 
(3 minute 3 changes) 
POLYMER-HRP 
Contains secondary antibody labelled with 
HRP enzyme. Add polymer-HRP and 
incubate for 20 minutes 
Wash with PBS 
3 minutes 3 changes 
DAB CHROMOGEN 
Prepare Dab Chromogen by adding 1 ml DAB 
buffer and one drop of DAB chromogen. Pour 
over tissue and incubate for 4 minutes 
Counter staining 
Imparts background staining  
Counter stain with hematoxylin for 
30 seconds and wash in running tap 
water 
Wash with distilled 
water (2 changes) 
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VEGF – Vascular Endothelial Growth Factor 
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ANNEXURE - F 
KEY TO MASTER CHART 
AUB – Abnormal Uterine Bleeding 
MR – Menorrhagia 
MTR – Metrorrhagia 
MMTR – Menometrorrhagia 
PMR – Polymenorrhea 
PMB – Postmenopausal Bleeding 
  
ANNEXURE – G: MASTER CHART 
S.№ NAME AGE  
HISTOPATHOLOGY 
№ 
I.P.№ PARITY 
CLINICAL FEATURES CLINICAL 
DIAGNOSIS 
USG 
FINDINGS 
HISTOPATHOLOGICAL DIAGNOSIS 
MR MTR MMTR PMR PMB 
1 Mrs Kumari 46 604/13 2907130010 P3 ＋         AUB ET-10mm Secretory pattern 
2 Mrs.Samans Mary 42 614/13 270713002 P3   ＋       AUB ET-8mm Secretory pattern 
3 Mrs.Padmavathy 45 641/13 0808130028 P2 ＋         AUB ET-7mm Proliferative pattern 
4 
Mrs Mohana 
Tirunavukarasu 
48 659/13 0708130013 P3   ＋       AUB ET-11mm Complex hyperplasia 
5 Mrs.Banumathy 65 671/13 0208130036 P4         ＋ AUB ET-4mm Atrophic endometrium 
6 Mrs.Lakshmi 45 726/13 0309130076 P3       ＋   AUB ET-10mm Simple hyperplasia 
7 Mrs.Sujatha 37 780/13 1010130008 P2   ＋       AUB ET-10mm Simple hyperplasia 
8 Mrs.Shanthi 50 782/13 0110130007 P3     ＋     AUB ET-7mm Chronic endometritis 
9 Mrs.Pushnavathi 43 796/13 1710130007 P2 ＋         AUB ET-6mm Atypical hyperplasia 
10 Mrs.Nagammal 60 809/13 0110130006 P4         ＋ AUB ET-6mm 
Squamous cell carcinoma infiltrating 
endometrium 
11 Mrs.Vasanthi 38 821/13 1710130022 P2 ＋         AUB ET-15mm Complex hyperplasia 
12 Mrs .Thangam 58 832/13 2810130015 P3         ＋ AUB ET-6mm Simple hyperplasia 
13 Mrs.Gomathi 42 865/13 1911130003 P3 ＋         AUB ET-5mm Menstrual phase 
14 Mrs.Manogari 30 916/13 1912130007 P2 ＋         AUB ET-6mm Complex hyperplasia 
15 Mrs.Chinnakulandhai 50 919/13 1612130029 P3   ＋       AUB ET-8mm Chronic endometritis 
16 Mrs.Shantha 48 925/13 2612130015 P3   ＋       AUB ET-4mm Secretory hyperplasia 
17 Mrs.Sumathi 36 926/13 2612130074 P2     ＋     AUB ET-11mm Atypical hyperplasia 
  
S.№ NAME AGE  
HISTOPATHOLOGY 
№ 
I.P.№ PARITY 
CLINICAL FEATURES CLINICAL 
DIAGNOSIS 
USG 
FINDINGS 
HISTOPATHOLOGICAL DIAGNOSIS 
MR MTR MMTR PMR PMB 
18 Mrs.Deepa 40 927/13 2612130016 P3 ＋         AUB ET-11mm Simple hyperplasia 
19 Mrs.Janagavali 40 039/14 1701140009 P3   ＋       AUB ET-9mm Secretory hyperplasia 
20 Mrs.Umamaheswari 42 046/14 2401140014 P2 ＋         AUB ET-5mm Secretory pattern 
21 Mrs.Valarmathy 42 051/14 0201140040 P2 ＋         AUB ET-6mm Secretory pattern 
22 Mrs.Chellammal 49 102/14 1002140062 P3   ＋       AUB ET-9mm Proliferative pattern 
23 Mrs.Amishiya 45 107/14 1202140042 P3 ＋         AUB ET-5mm Simple hyperplasia 
24 Mrs.Saraswathy 48 109/14 1302140030 P3 ＋         AUB ET-12mm Irregular shedding 
25 Mrs.Saraswathy 40 180/14 0803140004 P1 ＋         AUB ET-5mm Endometrial polyp 
26 Mrs.Sumathy 36 190/14 0503140021 P2   ＋       AUB ET-6mm Simple hyperplasia 
27 Mrs.Bhuvaneswari 40 206/14 1903140012 P3   ＋       AUB ET-11mm Simple hyperplasia 
28 Mrs.Selvi 50 213/14 2103140002 P2 ＋         AUB ET-10mm Simple hyperplasia 
29 Mrs.Jayanthi 32 226/14 1803140006 P2 ＋         AUB ET-6mm Secretory pattern 
30 Mrs.Rajeswari 38 230/14 2603140005 P2 ＋         AUB ET-13mm Secretory hyperplasia 
31 Mrs.Kamatchi 51 273/14 0704140004 P2         ＋ AUB ET-10mm Atrophic endometrium 
32 Mrs.Papammal 40 276/14 2703140045 P2   ＋       AUB ET-9mm Simple hyperplasia 
33 Mrs.Kasthuri 43 285/14 0404140051 P3   ＋       AUB ET-14mm Simple hyperplasia 
34 Mrs.Thayammal 38 295/14 1204140003 P2   ＋       AUB ET-15mm Atypical hyperplasia 
35 Mrs.Neela 40 296/14 0804140060 P3 ＋         AUB ET-6mm Secretory pattern 
36 Mrs.Vasntha 39 309/14 1504140013 P2 ＋         AUB ET-12mm Complex hyperplasia 
  
S.№ NAME AGE  
HISTOPATHOLOGY 
№ 
I.P.№ PARITY 
CLINICAL FEATURES CLINICAL 
DIAGNOSIS 
USG 
FINDINGS 
HISTOPATHOLOGICAL DIAGNOSIS 
MR MTR MMTR PMR PMB 
37 Mrs.Kanniga 42 314/14 1604140007 P2 ＋         AUB ET-5mm Complex hyperplasia 
38 Mrs.Lakshmi 49 323/14 1804140003 P3   ＋       AUB ET-10mm Endometrial adenocarcinoma 
39 Mrs .Chandra 48 324/14 1904140001 P2 ＋         AUB ET-6mm Atrophic endometrium 
40 Mrs.Suguna 42 359/14 2704140003 P3 ＋         AUB ET-6mm Menstrual phase 
41 Mrs.Vasantha 38 367/14 2804140029 P2 ＋         AUB ET-5mm Secretory pattern 
42 Mrs.Sathya 30 375/14 0505140047 P2 ＋         AUB ET-7mm 
Disordered proliferative 
endometrium 
43 Mrs.Sagunthala 45 388/14 0505140053 P2   ＋       AUB ET-10mm Complex hyperplasia 
44 Mrs.Kamatchi 37 389/14 0705140033 P2 ＋         AUB ET-11mm Simple hyperplasia 
45 Mrs.Radha 50 392/14 0505140049 P3 ＋         AUB ET-6mm Complex hyperplasia 
46 Mrs.Sellamallal 50 416/14 1205140053 P2 ＋         AUB ET-5mm Simple hyperplasia 
47 Mrs.Kanchana 44 419/14 1305140002 P2 ＋         AUB ET-8mm Complex hyperplasia 
48 Mrs.Ajantha 44 420/14 1405140046 P3   ＋       AUB ET-polyp Endometrial polyp 
49 Mrs.Eganthal 45 429/14 1505140052 P3 ＋         AUB ET-10mm Proliferative pattern 
50 Mrs.Dhanalakshmi 28 445/14 1505140046 P3 ＋         AUB ET-polyp Complex hyperplasia 
51 Mrs.Devi 28 452/14 2105140016 P2 ＋         AUB ET-6mm Simple hyperplasia 
52 Mrs.Panchalai 42 475/14 1505140054 P4 ＋         AUB ET-5mm Secretory pattern 
53 Mrs.Kasthuri 33 485/14 2905140009 P2 ＋         AUB ET-polyp Endometrial polyp 
54 Mrs.Pooniyammal 37 500/14 0306140008 P2 ＋         AUB ET-6mm Proliferative pattern 
55 Mrs.Sumathy 36 506/14 0506140001 P2 ＋         AUB ET-10mm Proliferative pattern 
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№ 
I.P.№ PARITY 
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HISTOPATHOLOGICAL DIAGNOSIS 
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56 Mrs.Barathi 23 516/14 0906140016 P2 ＋         AUB ET-6mm Menstrual phase 
57 Mrs.Saraswathy 48 545/14 1606140008 P4   ＋       AUB ET-5mm Simple hyperplasia 
58 Mrs.Vedhavalli 49 550/14 1906140049 P2 ＋         AUB ET-6mm Complex hyperplasia 
59 Mrs.Adhilakshmi 44 559/14 2106140007 P3 ＋         AUB ET-11mm Granulomatous TB 
60 Mrs.Poonammal 45 566/14 2306140003 P2 ＋         AUB ET-11mm Secretory hyperplasia 
61 
Mrs.Shanthi 
Mahadevan 
44 576/14 1006140046 P2   ＋       AUB 
ET-
pyometra 
Secretory pattern 
62 Mrs.Manjula 40 581/14 2706140004 P3   ＋       AUB ET-4mm Secretory pattern 
63 Mrs.Myli 29 622/14 0907140018 P2 ＋         AUB ET-15mm Proliferative pattern 
64 Mrs.Parvathy 40 643/14 1407140020 P2 ＋         AUB ET-6mm Menstrual phase 
65 Mrs.Alamelu 49 683/14 2607140044 P3 ＋         AUB ET-7mm Proliferative pattern 
66 Mrs.Dhavamani 32 688/14 3007140021 P2 ＋         AUB ET-7mm Simple hyperplasia 
67 Mrs.Chellamal 50 708/14 2107140011 P3   ＋       AUB ET-10mm Simple hyperplasia 
68 Mrs.Jaya 28 720/14 3107140047 P2 ＋         AUB ET-5mm Proliferative pattern 
69 Mrs.Kanaga 42 735/14 0808140007 P2   ＋       AUB ET-8mm Mixed pattern 
70 Mrs.Shanthi 47 736/14 01081400521 P2     ＋     AUB ET-10mm Simple hyperplasia 
71 Mrs.Bavani 38 738/14 0508140023 P2 ＋         AUB ET-11mm Simple hyperplasia 
72 Mrs.Geetha 54 743/14 0408140025 P3         ＋ AUB ET-11mm Simple hyperplasia 
73 Mrs.Renuga 46 753/14 0408140061 P3 ＋         AUB ET-10mm Proliferative pattern 
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74 Mrs.Susila 42 768/14 1608140009 P3   ＋       AUB ET-8mm 
Disordered proliferative 
endometrium 
75 Mrs.Yasodha 40 773/14 1808140070 P2 ＋         AUB ET-10mm 
Disordered proliferative 
endometrium 
76 Mrs.Lalitha 48 791/14 2308140011 P2 ＋         AUB ET-11mm Atypical hyperplasia 
77 Mrs.Dilliyammal 45 807/14 0308140014 P2 ＋         AUB ET-8mm Secretory pattern 
78 Mrs.Lakshmi Suresh 40 813/14 1508140011 P0 ＋         AUB ET-6mm Proliferative pattern 
79 
Mrs.Lakshmi 
Madhavan 
38 821/14 0109140032 P1 ＋         AUB ET-10mm Proliferative pattern 
80 Mrs.Ellammal 45 822/14 0209140015 P2     ＋     AUB ET-11mm Proliferative pattern 
81 Mrs.Sarasu 50 845/14 0809140021 P3   ＋       AUB ET-9mm 
Disordered proliferative 
endometrium 
82 Mrs.Kuppu 46 849/14 0609140056 P2 ＋         AUB ET-8mm Complex hyperplasia 
83 Mrs.Meena 50 860/14 0509140049 P2     ＋     AUB ET-9mm 
Disordered proliferative 
endometrium 
84 Mrs.Selvi 52 880/14 1809140011 P3         ＋ AUB ET-6mm 
Disordered proliferative 
endometrium 
85 Mrs.Munniyammal 40 882/14 2009140034 P2     ＋     AUB ET-5mm Secretory pattern 
86 Mrs.Poornima 30 892/14 2309140025 P1 ＋         AUB ET-11mm Arias stella effect 
87 Mrs.Lakshmi 44 893/14 2309140004 P2 ＋         AUB ET-5mm Proliferative pattern 
88 Mrs.Amudha 50 902/14 2509140029 P2 ＋         AUB ET-polyp Endometrial polyp 
89 Mrs. 52 924/14 2409140015 P4         ＋ AUB ET-12mm Endometrial adenocarcinoma 
90 Mrs.Selvi 35 935/14 0710140027 P2 ＋         AUB ET-polyp Endometrial polyp 
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91 Mrs.Vijaya 44 947/14 0910140019 P3   ＋       AuB ET-10mm Proliferative pattern 
92 Mrs.Rukumani 30 948/14 091040017 P2 ＋         AUB ET-6mm Proliferative pattern 
93 Mrs.Krishnamani 47 960/14 1110140034 P3 ＋         AUB ET-10mm Secretory pattern 
94 Mrs.Valli 38 969/14 0710140029 P2     ＋     AUB ET-11mm Simple hyperplasia 
95 Mrs.Latha 38 970/14 1410140025 P2 ＋         AUB ET-7mm 
Disordered proliferative 
endometrium 
96 Mrs.Kanniyammal 50 979/14 1610140010 P3   ＋       AUB ET-4mm Proliferative pattern 
97 Mrs.Sankari 41 996/14 2510140015 P2 ＋         AUB ET-5mm Secretory pattern 
98 Mrs.Karpagavalli 36 997/14 2310140025 P2 ＋         AUB ET-8mm Proliferative pattern 
99 Mrs.Dhulasi 60 1000/14 2710140024 P4         ＋ AUB ET-10mm Atrophic endometrium 
100 Mrs.Laksmi 39 1010/14 2910140001 P2 ＋         AUB ET-12mm Complex hyperplasia 
101 Mrs.Alamelu 45 1018/14 0111140033 P3 ＋         AUB ET-10mm Proliferative pattern 
102 Mrs.Malliga 50 1024/14 3110140077 P3   ＋       AUB ET-15mm Simple hyperplasia 
103 Mrs.Pushpavathy 41 1036/14 3110140003 P2       ＋   AUB ET-20mm Simple hyperplasia 
104 Mrs.Rukmani 33 1038/14 0811140035 P2 ＋         AUB ET-6mm Proliferative pattern 
105 Mrs.Sarasu 40 1045/14 1211140040 P2 ＋         AUB ET-12mm Proliferative pattern 
106 Mrs.Sathiya Priya 32 1060/14 1811140012 P2 ＋         AUB ET-15mm Simple hyperplasia 
107 Mrs.Thilagam 40 1073/14 2511140009 P2 ＋         AUB ET-14mm Simple hyperplasia 
108 Mrs.Paanjalai 52 1078/14 2411140036 P3         ＋ AUB ET-4mm Atrophic endometrium 
109 Mrs.Valliyammal 39 1080/14 2611140005 P2   ＋       AUB ET-10mm Simple hyperplasia 
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110 Mrs.Pongodi 43 1110/14 0412140008 P2 ＋         AUB ET-5mm Proliferative pattern 
111 Mrs.Sathyabama 48 1111/14 0412140014 P3 ＋         AUB ET-8mm Proliferative pattern 
112 Mrs.Munniyammal 54 1114/14 2811140050 P3         ＋ AUB ET-5mm Atrophic endometrium 
113 Mrs.Shakila 44 1140/14 11121400005 P2 ＋         AUB ET-17mm Simple hyperplasia 
114 Mrs.Selvi 32 1143/14 1212140018 P2 ＋         AUB ET-10mm Proliferative pattern 
115 Mrs.Elavarasi 50 1145/14 1212140008 P3   ＋       AUB ET-15mm Complex hyperplasia 
116 Mrs.Rani 45 1169/14 1612140018 P2     ＋     AUB ET-7mm Atrophic endometrium 
117 Mrs.Puspha 44 1184/14 1812140044 P2 ＋         AUB ET-polyp Endometrial polyp 
118 Mrs.Murugammal 45 1188/14 1312140012 P2 ＋         AUB ET-8mm Menstrual phase 
119 Mrs.Shanthi 38 1199/14 1312140018 P2 ＋         AUB ET-12mm 
Disordered proliferative 
endometrium 
120 Mrs.Kanagavalli 40 1202/14 2612140001 P3 ＋         AUB ET-10mm Secretory pattern 
121 Mrs.Chellammal 65 022/15 2212140008 P4         ＋ AUB ET-17mm Atypical hyperplasia 
122 Mrs.Kamatchi 33 026/15 0601150014 P2   ＋       AUB ET-15mm Simple hyperplasia 
123 Mrs.Mannikam 48 044/15 2201150005 P3 ＋         AUB ET-12mm Endometrial metaplasia 
124 Mrs.Akshiliya 50 083/15 2601150004 P3   ＋       AUB ET-11mm Proliferative pattern 
125 Mrs.Rathi 46 097/15 2901150046 P2 ＋         AUB ET-10mm Proliferative pattern 
126 Mrs.Sundari 30 103/15 3101150002 P2 ＋         AUB ET-12mm Secretory pattern 
127 Mrs.Lalitha 45 112/15 0302150005 P2 ＋         AUB ET-15mm Proliferative pattern 
128 Mrs.Jaclin 37 113/15 0302150002 P2   ＋       AUB ET-10mm Secretory pattern 
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129 Mrs.Thayar 35 114/15 0302150008 P2 ＋         AUB ET-12mm Proliferative pattern 
130 Mrs.Shanthi 40 117/15 2901150048 P2   ＋       AUB ET-18mm Complex hyperplasia 
131 Mrs.Patchyammal 45 118/15 0402150010 P2     ＋     AUB ET-6mm Proliferative pattern 
132 Mrs.Vasuki M 41 120/15 0402150009 P3 ＋         AUB ET-10mm Proliferative pattern 
133 Mrs.Selvi 42 133/15 0902150022 P3     ＋     AUB ET-6mm Hormonal changes 
134 Mrs.Malar 40 138/15 1002150053 P2     ＋     AUB ET-10mm Menstrual phase 
135 Mrs.Lakshmi 48 139/15 05021500109 P2 ＋         AUB ET-8mm Secretory pattern 
136 Mrs.Kavitha 35 155/15 1602150017 P1 ＋         AUB ET-10mm Proliferative pattern 
137 Mrs.Kalavathy 46 187/15 1702150039 P2   ＋       AUB ET-12mm Simple hyperplasia 
138 Mrs.Malliga 44 188/15 2602150039 P2 ＋         AUB ET-15mm Secretory pattern 
139 Mrs.Vijaya 40 195/15 2702150002 P2     ＋     AUB ET-10mm Simple hyperplasia 
140 Mrs.Kannagi 29 216/15 0403150004 P1 ＋         AUB ET-8mm Simple hyperplasia 
141 Mrs.Vijaya 45 231/15 1103150015 P2 ＋         AUB ET-10mm 
Disordered proliferative 
endometrium 
142 Mrs.Vijayalakshmi 40 241/15 0903150053 P2   ＋       AUB ET-8mm Secretory pattern 
143 Mrs.Mohana 34 255/15 1103150013 P1   ＋       AUB ET-10mm Proliferative pattern 
144 Mrs.Jayanthi 35 322/15 2503150020 P1 ＋         AUB ET-11mm Simple hyperplasia 
145 Mrs.Lakshmi 47 428/15 1604150042 P2   ＋       AUB ET-8mm Endometrial adenocarcinoma 
146 Mrs. Sathya 40 443/15 2104150029 P1 ＋         AUB ET-7mm Secretory pattern 
147 Mrs.Kanammal 39 457/15 2404150045 P2 ＋         AUB ET-10mm Simple hyperplasia 
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148 Mrs.Chellamal 55 458/15 1504150017 P2         ＋ AUB ET-4mm Atrophic endometrium 
149 Mrs.Rani 58 459/15 1604150031 P3         ＋ AUB ET-4mm Atrophic endometrium 
150 Mrs.Malar 42 467/15 2002150075 P2 ＋         AUB ET-7mm 
Disordered proliferative 
endometrium 
 
  
  
ER AND PR STATUS OF ENDOMETRIUM IN NON-MALIGNANT AND MALIGNANT 
ENDOMETRIUM 
S.№ NAME AGE  
HISTOPATHOLOGY 
№ 
HISTOPATHOLOGICAL 
DIAGNOSIS 
ER (PP %) PR (PP %) 
1 Mrs.Padmavathy 45 641/13 Proliferative pattern 90 98 
2 
Mrs Mohana 
Tirunavukarasu 
48 659/13 Complex hyperplasia 
0 0 
3 Mrs.Lakshmi 45 726/13 Simple hyperplasia 70 79 
4 Mrs.Pushnavathi 43 796/13 Atypical hyperplasia 54 53 
5 Mrs.Chellammal 49 102/14 Proliferative pattern 82 97 
6 Mrs.Amishiya 45 107/14 Simple hyperplasia 65 68 
7 Mrs.Selvi 50 213/14 Simple hyperplasia 60 53 
8 Mrs.Kasthuri 43 285/14 Simple hyperplasia 63 63 
9 Mrs.Kanniga 42 314/14 Complex hyperplasia 60 62 
10 Mrs.Lakshmi 49 323/14 Endometrial adenocarcinoma 29 27 
11 Mrs.Sagunthala 45 388/14 Complex hyperplasia 55 60 
12 Mrs.Radha 50 392/14 Complex hyperplasia 0 65 
13 Mrs.Sellamallal 50 416/14 Simple hyperplasia 0 0 
14 Mrs.Kanchana 44 419/14 Complex hyperplasia 59 57 
15 Mrs.Eganthal 45 429/14 Proliferative pattern 96 89 
16 Mrs.Saraswathy 48 545/14 Simple hyperplasia 48 60 
17 Mrs.Vedhavalli 49 550/14 Complex hyperplasia 59 63 
  
S.№ NAME AGE  
HISTOPATHOLOGY 
№ 
HISTOPATHOLOGICAL 
DIAGNOSIS 
ER (PP %) PR (PP %) 
18 Mrs.Alamelu 49 683/14 Proliferative pattern 97 99 
19 Mrs.Chellamal 50 708/14 Simple hyperplasia 59 67 
20 Mrs.Shanthi 47 736/14 Simple hyperplasia 0 0 
21 Mrs.Renuga 46 753/14 Proliferative pattern 88 92 
22 Mrs.Lalitha 48 791/14 Atypical hyperplasia 49 53 
23 Mrs.Ellammal 45 822/14 Proliferative pattern 85 89 
24 Mrs.Kuppu 46 849/14 Complex hyperplasia 60 63 
25 Mrs.Lakshmi 44 893/14 Proliferative pattern 98 95 
26 Mrs.Vijaya 44 947/14 Proliferative pattern 93 0 
27 Mrs.Kanniyammal 50 979/14 Proliferative pattern 0 0 
28 Mrs.Alamelu 45 1018/14 Proliferative pattern 89 94 
29 Mrs.Malliga 50 1024/14 Simple hyperplasia 68   
30 Mrs.Pushpavathy 41 1036/14 Simple hyperplasia 59 78 
31 Mrs.Pongodi 43 1110/14 Proliferative pattern 84 98 
32 Mrs.Sathyabama 48 1111/14 Proliferative pattern 94 92 
33 Mrs.Shakila 44 1140/14 Simple hyperplasia 59 68 
34 Mrs.Elavarasi 50 1145/14 Complex hyperplasia 57 55 
35 Mrs.Akshiliya 50 083/15 Proliferative pattern 97 91 
36 Mrs.Rathi 46 097/15 Proliferative pattern 0 0 
37 Mrs.Lalitha 45 112/15 Proliferative pattern 0 0 
  
S.№ NAME AGE  
HISTOPATHOLOGY 
№ 
HISTOPATHOLOGICAL 
DIAGNOSIS 
ER (PP %) PR (PP %) 
38 Mrs.Patchyammal 45 118/15 Proliferative pattern 98 96 
39 Mrs.Vasuki M 41 120/15 Proliferative pattern 92 97 
40 Mrs.Kalavathy 46 187/15 Simple hyperplasia 51 52 
41 Mrs.Lakshmi 47 428/15 Endometrial adenocarcinoma 26 0 
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